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ABSTRACT 
Previous published literature examining the impact of Fabry disease on female heterozygotes has 
suggested that women with this disease have a unique clinical relationship with the healthcare 
system and engage in Fabry disease medical management in a manner different from their male 
counterparts. The past history of labeling these women as carriers for the disease and asymptomatic 
has been proposed as one barrier to females’ participation in evaluation and monitoring for Fabry 
disease.  However, the health beliefs unique to females with Fabry disease have not been 
thoroughly addressed in the literature. We attempted to examine this issue in more detail utilizing 
the Health Belief Model, a conceptual framework to assess perceived susceptibility to and severity 
of a disease, perceived benefit of engaging in a health behavior, and perceived barriers to 
performing this behavior. This study, part two of a larger three part project, examines the health 
beliefs of 44 adult females diagnosed with Fabry disease from across the United States through 
the means of a concurrent demographic survey and written, multiple choice and open-ended health 
belief questionnaire.  Themes emerging from analysis of part one of the larger three part project, 
aimed at describing the health beliefs of ten females through qualitative thematic analysis, 
informed the design of the health belief questionnaire utilized in this study.   This study 
characterizes the health beliefs of a larger population of adult females diagnosed with Fabry 
disease than previously assessed in part one of the study, specifically assessing the perceived 
severity, perceived susceptibility, and perceived benefits of and barriers to treatment, evaluation, 
 v 
and monitoring, and identifies strategies to address identified barriers, modifying variables, and 
cues to action to improve communication between healthcare providers and their female patients.  
Strategies developed to identify and address these barriers may be applied to other populations of 
females diagnosed with genetic conditions in which poor compliance for recommended 
evaluations and monitoring have been documented, providing a broader application and public 
health significance to the findings of this study. 
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1.0  INTRODUCTION 
The Lysosomal Storage Disorders (LSD) Program at the University of Pittsburgh and the 
Children’s Hospital of Pittsburgh of UPMC is devoted to the care of individuals and families 
affected with and by lysosomal storage disorders.  David Finegold, MD and genetic counselor 
Katie Long, MS, CGC work in collaboration to provide comprehensive disease management to 
individuals diagnosed with lysosomal storage disorders, including an X-linked lysosomal disorder 
called Fabry disease.  Fabry disease is caused by a deficiency of the enzyme α-galactosidase and 
accumulation of the substrate globotriaosylceramide (GL3) in the vascular endothelial cells. 
Progressive GL3 accumulation leads to chronic, progressive multisystemic disease and end organ 
damage requiring management and monitoring from a team of specialists.1-4 Females heterozygous 
for GLA mutations were previously thought to be asymptomatic and not at-risk for the 
development of disease manifestations.5  It has since been demonstrated and accepted among the 
medical community that heterozygous females can be affected with the full spectrum of Fabry 
disease symptoms, although females typically have a more variable disease presentation when 
compared to affected males.6 
Female heterozygotes are at risk to suffer from significant multisystemic disease and 
should be monitored and treated accordingly.5  Recommendations for disease monitoring 
consisting of annual or semiannual evaluations from a team of multiple specialists are similar for 
both males and females affected with Fabry disease.  Currently, the only FDA approved treatment 
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clinically available in the United States for Fabry disease is enzyme replacement therapy (ERT) 
using agalsidase beta (Fabrazyme, Genzyme, Sanofi Inc.).7  While initiation of treatment for males 
is recommended by age 10 to 13 years of age regardless of disease burden, initiation of treatment 
for females is dependent on degree of disease symptomology.4; 8 The discrepancy in the 
management of females compared to males has the potential to result in miscommunication 
between patient and provider regarding disease severity and susceptibility, delayed treatment,  and 
possible debilitating progression of disease.9   
Dr. David Finegold and Katie Long developed a three-part project to further characterize 
the unique clinical experience and health beliefs of females diagnosed with or at-risk for Fabry 
disease based on family history in which this study is Part 2.  The project was inspired by an 
observation made in the care of their female patients with Fabry disease, in which they noted that 
their heterozygous female patients were not usually evaluated in the clinical setting unless they 
presented with serious complications of the disease, regardless of recommendations by health care 
professionals for regular evaluation.  This circumstance was consistent with the current medical 
literature, which noted that females generally denied the presence or risk to develop significant 
complications with their health and were more likely to attend genetic counseling and clinical 
evaluations with their affected sons and male relatives than for their own health care management.2; 
5 While it had been demonstrated that females had a unique clinical relationship with health care 
professionals and engaged in management differently than males, there was insufficient 
information as to the potential factors that could be preventing evaluation, monitoring and 
treatment and contributing to noncompliance.   
In an attempt to better understand the health beliefs unique to females with Fabry disease, 
ten interviews among females over the age of 18 affiliated with the Lysosomal Program and a 
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confirmed diagnosis of Fabry disease or diagnosis based on family history were conducted and 
analyzed. This consisted of Part 1 of the three-part project.  The investigators utilized the Health 
Belief Model as a framework to structure the aims of their study and the content of the interview 
questions.  The Health Belief Model is a multi-dimensional model designed to assess and 
understand the failed acceptance of disease prevention and screening strategies among populations 
by assessing the perceived severity, perceived susceptibility, perceived benefits, perceived 
barriers, modifying variables, cues to action, and self-efficacy.10 Analysis of the ten interviews 
was completed using qualitative thematic analysis, an approach to analysis of qualitative data that 
enables the identification, analysis, and reporting of patterns (themes) within data.11 This approach 
was utilized in order to gain a deeper understanding of females’ personal health beliefs and to 
address the lack of literature assessing the views and unique experiences of females with Fabry 
disease.   
Thematic analysis of the ten interview narratives suggested that participants generally 
believed that Fabry disease was a very serious disease. The majority identified it as life-
threatening, but some expressed uncertainty with regard to severity of the disease among females 
or felt there was a delay in the seriouness for females due to later onset of disease symptoms. When 
making a comparison to males, some females identified the disease was equal in severity to males 
while others felt it was not as serious for females in comparison to males. 
With regard to susceptibility to Fabry disease, participants demonstrated an appropriate 
understanding of the natural history of Fabry disease including the risk for renal, cardiac, and 
cerebrovascular disease among females with Fabry disease, but demonstrated a decreased personal 
susceptibility to Fabry disease manifestations. Some participants acknowledged that this was due 
to denial and an inability to emotionally handle the implications of being a symptomatic mother, 
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sister, daughter, or caretaker for a male relative who was also symptomatic. Therefore, subjects 
avoided thinking about their own personal risk. There were others, however, who expressed an 
inevitability to having complications of Fabry disease and likened themselves to family members 
who had died of kidney or cardiac disease. These women believed they were very susceptible to 
the symptoms of Fabry disease and expressed that they may not be able to change the outcome 
even with monitoring or treatment. Some believed that they would follow the family pattern of 
symptom expression and this either made them feel more susceptible or less susceptible to the 
symptoms of Fabry disease.  
With regard to benefit of evaluations, monitoring, and treatment, participants generally 
indicated early intervention could be helpful to preventing later disease symptoms but also felt this 
could be delayed until significant symptoms were present. This may be linked to the themes of 
guilt and denial that cause some women to suppress their personal needs. Others thought 
evaluations and monitoring could be helpful in assessing response to enzyme replacement therapy 
and determining if it was helpful to them.  
Themes regarding barriers to evaluations, monitoring, and treatment were both explicity 
stated by participants and explored through the analysis of the interviews.  Many participants’ 
responses throughout the interviews were permeated by profound denial, grief, guilt, excessive 
worry, and sadness that influenced decision making related to engaging in routine evaluations, 
monitoring, and treatment. Concern for the health outcomes of male relatives was commonly 
reported and identified as the role of the caretaker. Guilt appeared to be a theme playing a role in 
several participant responses regarding the need to be a caretaker despite a rational recognition 
that the participant did not choose to pass on the disease and does not choose to be “well” while 
her male family member is “sick”. There were also pervasive themes of duty and loyalty  among 
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women with a symptomatic male relative. Subjects who described their role as a caretaker also 
talked about how this perspective is actively passed down through generations of women in the 
family. The theme of modeling the caretaker behavior and discouraging self-focus among female 
relatives was noted in several participant responses. 
Table 1. Thematic analysis from Part 1: Barriers to evaluations, monitoring and treatment 
Anger Fear 
Burden on family Grief 
Carrier terminology Guilt 
Concern for employment or insurance 
discrimination 
Helplessness 
Caretaker role: Duty, loyalty, discouraging self 
focus 
Lack of support 
 
This current study, which is Part 2 of this project, utilized the themes described above that 
emerged from the transcripts in the aforementioned study (Part 1) to design a questionnaire to 
assess the health beliefs among a broader group of women diagnosed and at-risk for Fabry disease. 
The combined efforts of Part 1 and Part 2 will provide insight into the health beliefs of the Fabry 
female population with a specific interest is assessing barriers to engaging in preventative health 
behaviors and contributing to the development of strategies to address these barriers and improve 
patient compliance with recommended therapies. 
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1.1 SPECIFIC AIMS 
The specific aims of this project are as follows: (1) to design and administer to 50 females at risk 
or diagnosed with Fabry disease a clinical questionnaire to assess (2) perceived severity of Fabry 
disease, (3) perceived susceptibility to Fabry disease manifestations, (4) perceived benefits to 
engaging in clinical evaluation, monitoring and treatment, and (5) perceived barriers to clinical 
evaluation, monitoring and treatment. Additionally, as a sixth aim, (6) this study will attempt to 
identify differences among these females that affect their health beliefs, including those women 
who are on and are not on enzyme replacement therapy. 
1.2 BACKGROUND AND SIGNIFICANCE 
1.2.1 Fabry Disease 
Fabry disease is an X-linked lysosomal storage disorder that affects both males and females and 
results from a deficiency or absence of the enzyme α-galactosidase that leads to the progressive 
accumulation of globotriaosylceramide (GL3).12 Virtually any organ may be affected by Fabry 
disease with disease manifestations affecting the renal, cardiac, neurologic, cerebrovascular, 
gastrointestinal, ophthalmologic, and dermatologic systems.1-3 Fabry disease has no ethnic 
predilection and has an estimated incidence of 1 in 40,000 to 117,000 based on clinical 
ascertainment.6; 12; 13 Recent data from newborn screening initiatives and screening of high risk 
populations, however, suggests that the incidence may be greater than originally predicted.  The 
incidence from international efforts of newborn screening is estimated to range from 1 in 1,250 to 
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1 in 3,859.14-17 Studies have also found an increased incidence of Fabry disease, ranging from 1 in 
20 to 1 in 1,000, within high-risk populations including patients with cryptogenic strokes, 
hypertrophic cardiomyopathy, and those initiated on renal dialysis. 18; 19 
1.2.1.1 Molecular Genetics and Pathogenesis 
Fabry disease is caused by mutations in the gene GLA located on Xq22.1.  More than 431 mutations 
have been identified in GLA, the majority of which are private mutations.12  As the majority of 
mutations are unique to a specific family or individual, the genotype is generally not an accurate 
predictor for disease course or severity.6 Pathogenic mutations result in deficiency or absence of 
the enzyme α-galactosidase A, which functions to break down glycolipids within the lysosome.  
The enzyme deficiency results in the progressive accumulation of the substrate GL3 within the 
lysosomes of the cells in most organs, leading to cellular damage and organ dysfunction.  GL3 
accumulation is targeted within the glomular and tubular epithelial cells of the renal system, the 
myocardial cells and valvular fibrocytes of the cardiac system, neurons of the dorsal root ganglia 
of the autonomous nervous system, and the epithelial, perithelial, and smooth muscle cells of the 
vascular system.12 
1.2.1.2 Clinical Course of Fabry Disease 
Fabry disease is a chronic progressive condition with multisystemic disease resulting from 
lysosomal GL3 accumulation.  Although it was originally believed that females were not at risk to 
develop disease features, it is now accepted that female heterozygotes can be affected with Fabry 
disease symptoms.  The presentation and severity of manifestations of Fabry disease can differ 
between males and females, with females typically having a wider spectrum of disease severity 
presumably due to X-inactivation.6  Symptoms often begin in childhood, with the average age of 
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disease onset in males ranging from 6-8 years of age and an average age of disease onset in females 
of 9 years of age. Of note, there is great variability of disease presentation between individuals 
diagnosed with Fabry disease, even between individuals within the same kindred.20; 21 22 
Fabry disease manifestations involve the renal, cardiac, neurologic, cerebrovascular, 
gastrointestinal, ophthalmologic, and dermatologic systems, with significant morbidity and 
mortality attributed to progressive renal insufficiency, central and peripheral nervous system 
disease, and cardiovascular disease.2; 3; 23  Renal and cardiac diseases typically present in the 
second to third decades of life, but have been documented in affected individuals as early as 
childhood.20; 22 Renal manifestations include proteinuria, hypertension and chronic renal 
insufficiency.  End stage renal failure presents in approximately 31% of males and 1-4% of 
females, which can result in interventions including renal dialysis or renal transplantation. Cardiac 
disease includes conduction and valvular abnormalities, arrhythmias, cardiomyopathy, and left 
ventricular hypertrophy. Untreated cardiac manifestations can result in life threatening 
complications such as myocardial infarction and congestive heart failure.  Additionally, storage of 
GL3 within the vascular system increases the risk for severe manifestations including transient 
ischemic attacks (mini strokes) and strokes in individuals with Fabry disease. 2; 3; 19; 24-28 
 Neuropathic pain and gastrointestinal symptoms such as diarrhea, constipation and 
abdominal cramping are significant sources of burden that can contribute to poor quality of life for 
Fabry patients.  Pain consists of acroparesthesias (constant burning and tingling) particularly in 
the hands and feet, as well as episodic pain crises of severe, sharp neuropathic pain.29  Both 
symptoms begin in childhood and are the most common presenting symptoms for a person 
diagnosed with Fabry.20 19; 22 Additionally, individuals with Fabry disease suffer from other 
multisystemic symptoms including angiokeratoma, tinnitus, hearing loss, corneal whorls, vertigo, 
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obstructive pulmonary disease, and psychological conditions such as panic attacks, depression and 
adaptive functioning disorders.2; 3; 12; 19; 24-26; 30; 31 
Men and women diagnosed with Fabry disease have a shortened lifespan compared to their 
healthy counterparts.  The median age of death for men with Fabry disease is 58.2 years of age, 
which represents an approximate 16.5-year reduction of lifespan from the male general population. 
Women with Fabry disease typically have a more variable presentation and older age of onset than 
affected men.  The life expectancy for women with Fabry disease is approximately age 75.4, which 
is on average 4.6 years younger than the female general population.32 Life expectancy for males 
and females after treatment with enzyme replacement therapy has not yet been assessed; although 
it is suspected that the life expectancy would be improved.12 
1.2.1.3  Inheritance and Recurrence Risk  
Fabry disease is inherited in an X-linked manner.12  Previously it was believed that women were 
not at risk to develop disease manifestations, consistent with an X-linked recessive manner of 
inheritance. Females with a GLA mutation were presumed to be unaffected and were labeled 
“carriers” of Fabry disease.  It is has since been demonstrated that women are at risk to develop 
potentially all of the symptoms of Fabry disease, including serious manifestations such as stroke, 
renal failure, and cardiac disease. It is recommended that women with a GLA mutation be called 
“heterozygotes” and not “carriers” to prevent incorrect assumptions that females are not at risk for 
disease symptoms.6; 33; 34 Heterozygous women with Fabry disease have a 50% chance with each 
pregnancy to pass on the mutation for Fabry disease and have either an affected son or daughter 
who would be at risk for Fabry disease symptoms.  There is no male to male transmission of Fabry 
disease, but all daughters of affected men will inherit the mutated gene.19   
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1.2.1.4 Diagnosis 
Fabry disease is difficult to diagnose clinically as the symptoms are diverse and nonspecific, 
involve multiple organs, and can be easily confused with other pathologies.  Consequently, 
affected individuals can experience a  “diagnostic odyssey” resulting in an average of ten years of 
medical care with ten different medical specialists before receiving a confirmatory diagnosis of 
Fabry disease.6  Females with Fabry disease have an average 16.3-year delay in diagnosis from 
symptom onset.35 Suspicion for Fabry disease most often comes from nephrologists, 
dermatologists, ophthalmologists or geneticists.6   
When Fabry disease is suspected in an individual, confirmation of diagnosis is ascertained 
using different methods for males and for females.  Confirmation of diagnosis for hemizygous 
males with a suspicious family and/or medical history of Fabry disease is made by demonstrating 
absent or reduced α-galactosidase A enzymatic activity in blood leukocytes and/or plasma or by 
sequencing of the GLA gene. Diagnosis of heterozygous females is not based on enzyme analysis 
as women can have low or normal enzyme activity, leading to inconclusive results.  Direct 
sequencing of the gene GLA followed by deletion/duplication studies is the only reliable method 
to confirm diagnosis in suspected females.6; 12; 19 
The construction and interpretation of a targeted family history identifies at-risk family 
members and is an effective and efficient means for diagnosis of Fabry disease.  On average there 
are at least five family members who are diagnosed with Fabry disease after the initial proband is 
diagnosed.36  Typically, the initial proband will be male, however, subsequent diagnoses made 
from that initial diagnosis often result in the identification of heterozygous females with a more 
variable presentation of disease.6; 19 
 11 
1.2.1.5 Disease Management and Treatment 
Management of Fabry disease requires a comprehensive, multidisciplinary approach ideally 
conducted by medical specialists with experience treating its manifestations.  The number of body 
systems affected by the disease necessitates the involvement of multiple specialists in the care of 
an individual with Fabry disease.  Clear communication between these different medical 
professionals is essential to an effective team approach to disease management.  Comprehensive 
monitoring, regardless of age, sex and treatment status, should be conducted on a semiannual to 
annual basis and include monitoring by the following: nephrologists, cardiologists, neurologists, 
audiologists, ophthalmologists, pulmonologists, gastroenterologists, psychologists, and 
geneticists.4; 19; 24  Guidelines have been proposed by Eng et al. 2006 to manage both males and 
females diagnosed with Fabry disease (Table 2).4 
 
 
 
 
 
 
 
 
 
 
 
 
 12 
Table 2. Proposed assessments in Fabry disease patients, (adapted from Eng et al. 2006)4 
Organ System Assessment Intervals and/or Indications 
General  General status, school or work performance, mental health Baseline (at first visit), every 6 
months 
 
Complete physical examination, assessment of quality of life 
Genetic Counseling 
Genotype If not previously determined 
Kidney Serum electrolytes, creatinine, BUN; 24 hour urine or spot 
urine for total protein/creatinine, albumin/creatinine, sodium, 
creatinine, and (optional) GL-3 
Baseline.  
Every 3 month to every 12 mos. 
depending on the stage of chronic 
kidney disease (CKD) 
Cardiac Palpitations, angina Baseline, every 6 months 
Blood pressure, rhythm Every evaluation visit 
Electrocardiography and echocardiography Baseline.  Every 2 years for patients 
≤35 years, every year thereafter 
30-day holter monitoring If an arrhythmia is suspected or 
palpitations are present 
Cardiac MRI Optional 
Neurologic Acroparesthesias, fatigue, fever, sweating, heat and cold 
intolerance, joint pains, stroke-related symptoms, TIA 
Baseline, every 6 months 
Neurologic exam, Pain assessment Baseline, every 6 months 
Brain MRI without contrast Baseline.   
If TIA or stroke event  
In females to document CNS 
involvement 
Comorbid stroke risk factors: Cholesterol (Total, LDL, HDL), 
triglycerides, Lipoprotein A, total plasma homocysteine, factor 
V Leiden (G1691A), Protein C, Protein S, prothrombin 
G20210A, antithrombin III, anticardiolipin, lupus 
anticoagulant 
Baseline 
Every 12 months 
ENT Tinnitus, hearing loss, vertigo, dizziness Baseline, every 6 months 
Audiometry, tympanometry, otoacoustic emissions Baseline, yearly thereafter 
Ophthalmologic Visual disturbances, light sensitivity Baseline, every 6 months 
General ophthalmologic exam  Baseline, every 12 months 
Pulmonology Cough, exertional dyspnea, wheezing, exercise intolerance Baseline, every 6 months 
Spirometry, including response to bronchodilators, treadmill 
exercise testing, oximetry, chest X-ray 
Baseline, every 2 years or more 
frequently for clinical indications 
Gastrointestinal Postprandial abdominal pain, bloating, diarrhea, nausea, 
vomiting, early satiety, difficulty gaining weight 
Baseline, every 6 months 
 
 In 2003 the US Food and Drug Administration (FDA) approved agalsidase beta 
(Fabrazyme, Genzyme, Sanofi Inc) intravenous enzyme replacement therapy (ERT) for treatment 
of Fabry disease in both males and females.  Individuals receiving ERT typically require 
intravenous administration of therapy once every two weeks, a procedure that in most instances 
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can eventually be moved into the home to be administered by a trained home care nurse.  The 
decision to start treatment for an individual is largely based on clinical assessment, but is 
recommended to be initiated by age 10 to 13 years of age for affected males due to known natural 
history of untreated Fabry disease.8  In contrast to males, the decision to initiate ERT for females 
is dependent upon the presence of significant symptoms or progressive end organ involvement and 
not based on age.  Specific symptoms and measurements of biomarkers for clinical manifestations 
have been outlined by Eng et al. to determine if and when a female should be initiated with ERT.4   
Several studies have been conducted to better quantify potential clinical benefit from the 
administration of agalsidase beta. Clinical benefit of agalsidase beta has been demonstrated in 
multiple clinical trials by the effective reduction of plasma and tissue GL3 (a biomarker used to 
monitor disease progression) in the vascular endothelium of the kidney, skin and heart.37-39  Studies 
have also suggested that ERT decreases pain and improves quality of life for affected men and 
women.40; 41 There is debate among clinicians who manage patients with Fabry disease with regard 
to the timing of the initiation of ERT. A recent study suggested that the earlier ERT is begun the 
greater clinical benefit with regard to renal disease.  This recommendation is based on findings 
that long-term ERT use in young patients (as young as age 7) results in complete clearance of GL3 
in the mesengial and glomerular endothelial cells of the kidney with dose dependent clearance of 
the renal podocyte inclusions.42 The study population consisted of eleven males and one female 
and had a median age of 16.5 years with an age range of 7 to 33.  Still, some physicians believe 
that mindful watching is preferable to presymptomatic initiation of treatment. Although evidence 
suggests ERT provides some degree of clinical benefit to men and women with Fabry disease, 
treatment does not reverse or completely prevent end organ damage.  Adjunctive therapies, 
specifically for proteinuria, hypertension, stroke prevention, gastrointestinal distress, and 
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depression, and disease monitoring are still indicated when individuals are treated with ERT.12   
This means that current treatment options for Fabry disease do not necessarily decrease the number 
of tests or doctors visits required to manage disease features. 
Psychosocial issues and demanding disease-monitoring recommendations have the 
potential to act as barriers to disease treatment, evaluation, and monitoring.  Barriers to treatment 
with enzyme replacement therapy currently demonstrated in the literature include time constraints 
and conflicts with schedules, financial resources, medical insurance, fear and distrust of treatment, 
and risk of infusion reactions to ERT.43  It is possible that fear and distrust of treatment was 
identified around the time of ERT development because there was a lack of experience with this 
treatment in the Fabry disease community.  The research that examines barriers includes both 
males and females Fabry patients thus making it difficult to discern whether there might be barriers 
unique to females receiving ERT. 
Although some degree of efficacy of treatment with ERT has been shown in the literature, 
long-term clinical benefits remain unclear especially with regards to stroke prevention.7; 44; 45  The 
high cost of lifelong treatment, potential for immune reactions, and the need for repeated 
administration of large amounts of enzyme may acts as burdens to Fabry disease patients.  In 
addition, this methodology of treatment is unable to cross the blood brain barrier and treat 
neurologic complications.7  Efforts are currently being made to provide alternative treatments for 
Fabry disease in the United States including substrate reduction therapy, residual enzyme 
activators, chemical chaperone therapy, GLA promoter activity, protein homeostasis regulation, 
next generation ERT, and gene therapy. A number of treatments are still in the early forms of 
research and development.  However, one form of substrate reduction therapy (Amicus, AT1001) 
is currently being studied in phase III clinical trials.  Substrate reduction therapy is designed to 
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stabilize the naturally occurring enzyme in individuals and is suspected to increase enzyme 
activity.7; 12; 38; 46; 47 Additional and/or improved treatments have the potential to improve the care 
and quality of life of individuals with Fabry disease.   
1.2.2 Psychosocial Issues Associated with Fabry Disease 
Individuals with Fabry disease are at an increased risk for mental health issues as compared to the 
general population.  Depression and anxiety have been cited as both clinical features and 
psychosocial issues associated with Fabry disease.  Originally thought to be a secondary 
complication from chronic disease, depression and anxiety were accepted as primary disease 
complications in 2002 with the discovery of white matter changes in the brain detected by magnetic 
resonance imaging (MRI).  Depression and anxiety as a result of white matter disease is thought 
to be exacerbated by secondary complications including unpredictability of pain and 
gastrointestinal symptoms, increasing disability, and awareness of shortened lifespan.29  
Furthermore, psychological issues related to a genetic diagnosis in general may further complicate 
the mental health of an individual with Fabry disease including denial, anxiety, anger, grief, 
survivor and parental guilt, blame, depression, isolation, inability to cope, hopelessness, damage 
to self-esteem, changed relationship with family of origin, and change in sense of identity.24 
Studies of psychological dysfunction and mental health impairment have largely been 
conducted in affected males to date. The rates of depression, marital problems, unemployment, 
and suicide are higher in males with Fabry disease in comparison to their healthy counterparts.2; 24 
Disfiguring angiokeratomas can be a significant source of embarrassment and distress for 
individuals with Fabry disease.  Additionally, angiokeratomas located on the genitalia as well as 
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symptoms including chronic pain and fatigue may serve as barriers to the initiation and 
continuation of sexual relationships.3; 24; 26   
More recent initiatives to evaluate the psychological aspects of Fabry disease have 
attempted to examine populations of both males and females affected with Fabry disease.  Crosbie 
et al. 2009 evaluated the psychological functioning of 28 males and females with Fabry disease 
using the Minnesota Multiphasic Personality Inventory (MMPI-2), a measure widely used in 
chronic illness and chronic pain populations.  Both males and females with Fabry disease were 
found to have significant psychological distress and a pessimistic attitude toward the future.  In 
addition, these individuals demonstrated increased suspiciousness of others, which could result in 
increased apprehensive behavior, anger, and resentment.  The results of the study suggested that 
individuals with Fabry disease isolate themselves from others, may express defensiveness, and 
have the potential to minimize psychopathology when confronted about their mental health.  When 
compared to chronic pain patient populations, Fabry disease patients scored comparatively on the 
MMPI-2 scales, underscoring the physical suffering that Fabry disease patients feel.43  Laney et 
al. 2009 examined the social-adaptive and psychological functioning of 33 males and females with 
Fabry disease using the Diagnostic and statistical manual of mental disorders IV (DSM-IV) 
criteria and various aspects of daily life.  Patients with Fabry disease were found to have poorer 
adaptive functioning correlating with increased rates of depression, anxiety, depression and 
anxiety, antisocial personality, attention-deficit/hyperactivity, hyperactivity-impulsivity, and 
aggressive behavior.  The study concluded that the neuropsychological impact of Fabry disease on 
the day-to-day activities of affected males and females is likely underappreciated by health care 
providers.31   
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1.2.3 Psychological Burden and Quality of Life among Female Heterozygotes 
While recent measures have been taken to incorporate females into the assessment of Fabry disease 
burden including psychological functioning and quality of life, few studies have focused solely on 
the unique concerns of affected females.  A large-scale assessment of 202 females with Fabry 
disease was completed in 2006 by Street et al. to delineate the quality of life among heterozygous 
females.  Females within this population were found to have decreased quality of life compared to 
a control population from the Women’s Health Initiative, a large prospective study of 
postmenopausal women with the goal of identifying health behaviors, disease predictors, and 
approaches to disease prevention.  Females with Fabry disease were also found to have decreased 
emotional health, energy and general health when compared to a population of men and women 
with rheumatoid arthritis and increased pain and burden of disease when compared to a population 
of men and women with multiple sclerosis.48  In 2007 Wang et al. confirmed within a population 
of 44 affected females the prevalence of an overall reduced quality of life, but found this reduction 
was due to fatigue, exercise intolerance, and poor self-perception of health.  In addition to these 
factors, pain contributed to a high prevalence of depression and anxiety for study participants.5 
While these studies provide evidence that females have significant psychological distress and 
burden from Fabry disease, further studies are needed to more comprehensively understand the 
experience of heterozygous females and to differentiate potential psychosocial differences 
between affected males and females. 
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1.2.4 Barriers to Healthcare for Female Heterozygotes 
In 2008 Gibas et al. hypothesized that females with Fabry disease experienced unique barriers to 
healthcare and treatment due to a “triple disadvantage” from disease rarity, devalued carrier status, 
and gender.  In the analysis of 51 females with Fabry disease it was noted that females have a 
history of being labeled less credible, more problematic patients when compared to males and that 
labeling females as asymptomatic carriers may cause them to be ignored, dismissed, and 
disbelieved by some healthcare professionals.  Gibas et al. argues for the critical role of genetic 
counselors as advocates for women with Fabry disease to health care providers to help mitigate 
the potential consequences of problematic interactions between providers and patients.9  While 
this study provides valuable insight into potential barriers for females, this study is limited by the 
scope of the study design, which included a questionnaire asking participants about their 
experiences only with neuropathic pain and not explicitly about their experiences with healthcare 
professions. The authors of this study recommend future studies incorporate personal interviews 
with female heterozygotes to gather more specific information about interactions with and barriers 
to healthcare. 
1.2.5 The Health Belief Model 
The Health Belief Model is a multi-dimensional model defined in the 1970s to assess and 
understand the failed acceptance of disease prevention and screening strategies among 
populations.10 This model incorporates assessments including an individuals’ perceived 
susceptibility to a disease/condition, perceived severity of the disease/condition, perceived benefit 
of engaging in a health behavior, and perceived barriers to performing this behavior.49 
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Comprehensive review of this model after ten years of use by researchers found that perceived 
barriers is the most powerful of the dimensions in the Health Belief Model. Perceived susceptibility 
was determined to be a significant contributor to engaging in preventive health behaviors while 
perceived benefit was also a significant contributor but to a lesser degree. Perceived severity was 
found to be only weakly associated with preventive health behaviors.10 
 In 1988 self-efficacy was added to the four components of the Health Belief Model.  Self-
efficacy refers to an individual’s perception that he or she is competent to successfully perform a 
behavior and is a key component of health behavior change.50 The Health Belief Model suggests 
that individual characteristics act as modifying variables that indirectly affect health-related 
behaviors by impacting perceived severity, perceived susceptibility, perceived benefits and 
perceived barriers.  Modifying variables can include demographic, psychosocial, or structural 
variables.  Psychosocial variables include personality, social class, and pressure from peer groups.  
Structural variables include prior knowledge and/or contact with a disease, among other 
variables.51   In addition, the Health Belief Model theorizes that a trigger, or a cue to action, is 
necessary for prompting engagement in health behaviors.  Cues to action may be internal, such as 
physiological symptoms, or external, such as information from media or healthcare providers.10     
 There is extensive literature on the Health Belief Model and a complete review of the 
literature is beyond the scope of this thesis.  However, the Health Belief Model has been utilized 
to study issues related to genetic diagnoses and genetic counseling.  For example, the Health Belief 
Model has been used to study issues such as uptake of genetic testing, compliance with 
recommended management,  and the effectiveness of genetic counseling.52-56 Characterization of 
the health beliefs of individuals with genetic conditions has led to the development of strategies to 
improve patient compliance and patient communication with health professionals.52; 55; 56  Multiple 
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studies have examined aspects of genetic testing, genetic counseling, and recommended 
management for individuals with genetic predispositions to both breast and colorectal cancer using 
the Health Belief Model as a framework.52-54  Assessment of the health beliefs of individuals within 
these populations has aided in the development of strategies to improve decision-making with 
regard to genetic testing and to provide more effective genetic counseling strategies within cancer 
genetics.52-54 The Health Belief Model has also been utilized to improve prenatal genetic 
counselors’ facilitation of the decision-making process for the utilization of amniocentesis, an 
invasive procedure performed during pregnancy to provide chromosomal analysis of the fetus, for 
females of advanced maternal age.55 Finally, the Health Belief Model was successfully employed 
in 2007 by Gustafson et al. as a means to assess poor understanding of disease prevention and 
screening for African American females with sickle cell disease, an autosomal recessive genetic 
condition prevalent in individuals of African American ethnicity.56 
1.2.6 Qualitative Research 
1.2.6.1 Qualitative Research Methods 
A review of the literature revealed only two studies that assessed the psychological burden unique 
to females with Fabry disease, both of which utilized a quantitative approach. While these studies 
provide valuable information regarding the unique psychosocial concerns of females with Fabry 
disease, however they do not allow the researcher to characterize issues that may be unanticipated 
or considered important by the participants.  Qualitative descriptive analysis, however, enables 
investigators to discover and document aspects of reality that cannot be anticipated, making it a 
particularly effective approach to characterize a minimally explored circumstance such as the 
health beliefs of females with Fabry disease.57 
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Qualitative descriptive studies aim to study the world from the perspective of an individual. 
This research methodology is often about exploring meaning, attempting to explain what people 
do and why they do it.57 Description from this analysis, largely gathered from open ended 
questions, is particularly effective in obtaining answers to questions of relevance to practitioners, 
such as physicians or genetic counselors.58 Healthcare providers can use information gathered from 
qualitative analysis to improve their interactions with patients and reduce miscommunication.  
Furthermore, this analysis provides a description of events in the everyday terms of those events, 
meaning the conclusions from a study can reflect the experience of a participant in his or her own 
words.57  This in turn allows for healthcare providers to explore and address potential barriers and 
burdens for their patients in a more effective way, utilizing the language patients use themselves. 
1.2.6.2 Thematic Analysis 
Thematic analysis is a type of qualitative analysis that enables the identification, analysis, and 
reporting of patterns (themes) within data.  A theme is defined as a pattern that captures something 
important about the data in relation to the research question and represents some level of meaning 
within the data set.  Thematic analysis allows for either the rich description of a broad research 
question or a more nuanced and complex description of a particular theme.11  Both applications of 
thematic analysis allow for the ability to characterize unexplored circumstances that may not have 
been addressed in the literature.  In addition, this approach is a relatively quick and easy technique 
for new researchers to learn and can be used under a number of qualitative theoretical frameworks, 
making it a flexible and comprehensive framework in which to perform qualitative analysis.  A 
drawback to thematic analysis, however, is that the methodology is not well described and is open 
to interpretation.11   
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2.0  EXPERIMENTAL DESIGN AND METHODS 
The study design was originally approved by the University of Pittsburgh’s Institutional Review 
Board (IRB) on, August 11, 2010 and renewed yearly with the most recent renewal on May 22, 
2013 (Replications of IRB Approval letters for protocol # REN11070017/PRO10060403 can be 
found in Appendix A).  This study was funded by Genzyme, a subsidiary of Sanofi. 
2.1 PARTICIPANT RECRUITMENT 
This study was designed to recruit females over the age of 18 who were diagnosed with or at-risk 
for Fabry disease based on family history.  Hospital and clinic sites with a known Fabry disease 
patient population from across the United States of America were contacted to distribute 
participant recruitment flyers (Appendix B) to adult females diagnosed or at-risk for Fabry disease 
within their care.  Of those contacted, 14 clinical sites (Table 3) specializing in Fabry disease 
agreed to distribute the flyers to their adult female patients.  Interested participants contacted the 
Principle Investigator (PI), Katie Long, by phone or email and were consented over the phone by 
the PI or other approved investigators using a telephone script (Appendix C).  Participants who 
agreed to participate in the study were then mailed the demographic survey, clinical questionnaire, 
and a pre-paid, addressed envelope to mail the completed materials back to the PI.  It was decided 
not to use electronic survey methods as a means for participants to complete the materials to 
prevent the exclusion of potential participants without computer or internet access.  Upon receipt 
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of the completed demographic surveys and clinical questionnaires participants were mailed a $20 
debit card and a thank you flyer (Appendix D) in appreciation for their participation. 
Table 3. Participating Hospital and Clinic Sites 
Cedars Sinai 
(Los Angeles, CA) 
Indiana University  
(Indianapolis, IN) 
Children's Hospital of Philadelphia  
(Philadelphia, PA) 
Ann & H. Robert Lurie Children’s Hospital 
of Chicago  
(Chicago, IL) 
Children's Mercy Hospitals and Clinics 
(Kansas City, MO) 
Massachusetts General Hospital  
(Boston, MA) 
Children’s Hospital of Pittsburgh  
(Pittsburgh, PA) 
Northwest Oncology and Hematology  
(Coral Spring, FL) 
Children’s Hospital of Wisconsin  
(Milwaukee, WI) 
University of Colorado Hospital  
(Aurora, CO) 
Cincinnati Children’s Hospital  
(Cincinnati, OH) 
University of Washington  
(Seattle, WA) 
Emory Genetics  
(Atlanta, GA) 
Weisskopf Child Evaluation Center 
(Louisville, KY) 
 
2.2 DEMOGRAPHIC SURVEY 
Each participant was asked to complete a survey designed to characterize demographics and 
information about the individual’s family history of Fabry disease (Appendix E).  The survey was 
designed to take approximately five to ten minutes and consisted of twelve questions.  Information 
gathered from the administration of this survey was compiled using Microsoft Excel.   
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2.3 QUESTIONNAIRE 
Participants were asked to complete a clinical questionnaire designed to elicit their health beliefs 
including: perceived severity of Fabry disease, perceived susceptibility to Fabry disease, and 
perceived benefits and barriers to treatment, evaluation and monitoring (Appendix F).  
Questionnaires were designed to take approximately twenty minutes and consisted of twelve 
questions designed in a multiple choice, binary yes or no, checklist, or open ended format.  The 
results from the thematic analysis from Part 1 of this project were used to design the content of the 
questionnaire. Information gathered from the administration of this questionnaire included both 
quantitative and qualitative data.  Analysis of the data included the use of Microsoft Excel and 
thematic analysis, respectively. 
2.4 QUANTITATIVE ANALYSIS 
Data from the demographic surveys and questionnaires including the multiple choice and checklist 
questions were compiled using Microsoft Excel.  Descriptive statistical analysis was performed 
using Microsoft Excel. Further statistical analysis comparing variables for statistical significance 
was completed using R software.  Analyses included McNemar’s test of homogeneity, Logistic 
Regression, Fisher’s exact test, Friedman’s test, and the Wilcoxon test.  P-vales were adjusted, as 
needed, using the Bonferroni correction (α/N) for multiple comparisons. 
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2.5 QUALITATIVE ANALYSIS 
Data from the open ended questions in the clinical questionnaires were transcribed into an 
electronic format using Microsoft Word.  Transcripts adhered to participants’ grammar and 
spelling. Thematic analysis of the open ended responses were completed using guidelines proposed 
by Braun et al. (2006).  All transcripts were read by the author prior to the coding of the data in 
order to gain an appreciation of the scope of the data set.  In addition, a comprehensive literature 
review, as summarized in the Background and Significance section, was completed prior to 
analysis. Thematic analysis can be conducted in either an inductive or theoretical manner.  
Inductive analysis generates a more data driven analysis and is particularly effective with regard 
to a research question that has little data in the literature.  Theoretical thematic analysis, however, 
is more explicitly analyst-driven and is derived from pre-existing theories or preconceptions of the 
researcher from the literature.11  Inductive thematic analysis was utilized in this study.  Codes 
based on initially noted interesting features were generated and applied to the data in a systematic 
fashion.  Codes were collated into potential themes and the corresponding responses were 
reviewed for congruency. Themes identified in the data set can either be semantically or latently 
derived.  A semantic approach identifies themes within the explicit or surface meanings of data, 
whereas a latent approach involves interpretation of a deeper, underlying meaning to the theme.11  
Both approaches were appropriate for the generation of themes from the open ended responses and 
were utilized in the analysis to provide a thorough description of the data.  Potential themes were 
refined and finalized based on continued review of and comparison to the raw free-response data, 
literature review, and the specific aims of the study.11 
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3.0 RESULTS 
3.1 DEMOGRAPHICS 
A total of 44 females diagnosed with Fabry disease completed the survey and questionnaire.  The 
average age of participants was 49 years with a median age of 50 years and an age range of 26 to 
73 years.  Of those females, 100% were White and one individual indicated she was both White 
and American Indian/Alaska Native.  All of the participants (100%) were diagnosed with Fabry 
disease.  The majority of participants made a total household income of $35,000 or greater (71%) 
with the greatest percentage of participants indicating an income of greater than $75,000 (32%).  
The educational background of the participants largely consisted of at least one to three years of 
college (32%) or four years or more of college (32%).  When asked about marital status, 
approximately 23% of participants were single, 57% were married, 16% were divorced, and 5% 
were widowed.  Approximately 50% of participants were employed (part time or full time), 95% 
had some form of healthcare insurance, and 18% could not go to the doctor within the last year 
due to healthcare costs (Table 4). 
Table 4. Participant Demographics 
Demographics % of subjects Demographics % of subjects 
Age 
Mean 
Median 
Range 
49 years 
50 years 
26-73 years 
Insurance Status 
Insured 
Uninsured 
Unsure 
95.45% 
2.27% 
2.27% 
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Race 
Caucasian 
American Indian, Alaska Native 
100% 
2.27% 
Employment 
Full or part time 
Unemployed 
50.00% 
50.00% 
Income 
<10,000 
10,000-20,000 
20,001-35,000 
35,001-50,000 
50,001-75,000 
>75,000 
9.76% 
9.76% 
9.76% 
19.51% 
19.51% 
31.71% 
Education: Highest Level 
Grade 8 or less  
Grades 9-11 
Grade 12 or GED 
College 1 yr-3 yr 
College >4 yr 
Graduate Level 
0.00% 
4.55% 
6.82% 
31.82% 
31.82% 
25.00% 
Marital Status 
Single 
Married 
Divorced 
Separated 
Widowed 
22.73% 
56.82% 
15.91% 
0.00% 
4.55% 
Prevention of healthcare due 
to cost 
Yes 
No 
18.18% 
81.82% 
Diagnosed 
Yes 
No 
100% 
0% 
N=44 
*3 participants did not indicate income
3.1.1 Regional distribution of participants in the United States 
Participant recruitment flyers were initially distributed to eight clinical sites: Emory Genetics, 
Massachusetts General Hospital, University of Washington, Ann and H. Robert Lurie Children’s 
Hospital of Chicago, Weisskopf Child Evaluation Center, Cincinnati Children’s Hospital, 
Children’s Hospital of Wisconsin, and the University of Colorado Hospital.  Participants were 
asked to indicate which of these centers managed their Fabry disease or to mark “Other” and write 
the center or clinic that managed their disease in the corresponding blank.  Additional clinic sites 
were contacted for distribution of participant recruitment flyers.  The percentages of participants 
from participating sites were as follows: Emory Genetics (12.5%), Massachusetts General Hospital 
Table 4 Continued
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(4.6%), University of Washington (6.8%), Ann and H. Robert Lurie Children’s Hospital of 
Chicago (14.8%), Weisskopf Child Evaluation Center (6.8%), Cincinnati Children’s Hospital 
(11.4%), Children’s Hospital of Wisconsin (0%), the University of Colorado Hospital (2.3%), 
Cedars Sinai (2.3%), Children's Mercy Hospitals and Clinics (0%), Children's Hospital of 
Philadelphia (0%), Indiana University (4.6%), Northwest Oncology and Hematology (0%), and 
Children’s Hospital of Pittsburgh (6.8%) (Figure 1).  Clinic sites listed by participants that were 
not participating clinic sites included the University of Utah, the Lysosomal Storage Disease 
Clinical Care Network, O&O Alpan, Dartmouth-Hitchcock Medical Center, primary care 
physician, Denver Nephrology, Mt Sinai Hospital, Central Dupage Hospital, and no current 
management of Fabry disease symptoms (Table 5).  Centers providing management for 
participants were localized in regions using the Census Regions and Divisions of the United States 
(Appendix G).  Participating sites and clinics listed by participants under “Other” were included 
in this analysis. Approximately 15% of participants were from the Northeast, 24% were from the 
South, 32% were from the Midwest, 16% were from the West, and 14% of participants were unable 
to be localized to a region either due to lack of current management or non-localizable management 
(Figure 2). 
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 Figure 1. Proportion of participants managed at participating clinic sites (N=44)  
 
Table 5. Clinic sites listed under “Other”  
Additional clinic sites  Percentage of subjects 
Currently none (n/a) 4.5% 
Lysosomal Storage Disorders Clinical Disease Network (n/a) 2.3% 
O&O Alpan (Fairfax, VA) 2.3% 
University of Utah (Salt Lake City, Utah) 2.3% 
Medical University of South Carolina (Charleston, SC) 2.3% 
Primary care physician (n/a) 2.3% 
Denver Nephrology (Denver, CO) 2.3% 
Dartmouth-Hitchcock Medical Center (Lebanon, NH) 2.3% 
Did not disclose (n/a) 2.3% 
Many years ago- through a blood test (n/a) 2.3% 
Central Dupage Hospital (Winfeild, IL) 1.1% 
Mt Sinai (New York, NY) 1.1% 
Total participants marked “Other” 27.3% 
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Figure 2. Distribution of Fabry disease managing clinic sites by region in the United States (N=44) 
3.1.2 Family history of Fabry disease 
The majority of participants (98%) had a family history of Fabry disease.  Approximately 42% of 
participants had a son and/or daughter diagnosed with Fabry disease.  Of the 43 participants who 
indicated a family history of Fabry disease, approximately 56% indicated maternally inherited 
disease, 40% indicated paternally inherited disease, and 4% marked relatives without a designated 
maternal or paternal inheritance (i.e. sister, brother, son, daughter, niece, nephew) (Figures 3-5). 
The most common relative indicated was mother, followed by sister, father, daughter, and son 
(Table 6).  
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Figure 3. Proportion of participants with a family history of Fabry disease (N=44) 
 
 
Figure 4. Proportion of participants with a son and/or daughter diagnosed with Fabry disease (N=43) 
98%
2%
Family history
No family history
42%58%
Affected children
No affected children
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Figure 5. Origin of inheritance of Fabry disease (N=43) 
 
Table 6. Percentage of individual relatives with Fabry disease (N=43) 
Relative Percentage indicated by subjects 
Mother 46.5% 
Sister 41.9% 
Father 39.5% 
Son 37.2% 
Daughter 27.9% 
Maternal Cousin 27.9% 
Brother 23.3% 
Maternal Aunt 23.3% 
Niece 23.3% 
Paternal Grandmother 23.3% 
Maternal Grandfather 16.3% 
Maternal Grandmother 16.3% 
Maternal Uncle 16.3% 
Paternal Uncle 16.3% 
Paternal Cousin 16.3% 
Nephew 14.0% 
Paternal Aunt 9.3% 
Paternal Grandmother 0.0% 
 
56%40%
4%
Maternal
Paternal
Other/Unknown
 33 
3.1.3 Treatment of relatives with ERT 
Of the 43 participants who indicated that they had a family history of Fabry disease, 86% had 
relatives who had been treated with ERT (Figure 6). 
 
Figure 6. Percentage of participants’ relatives treated with ERT (N=43) 
3.2 SPECIFIC AIM TWO 
3.2.1 Perceived severity 
Participants were asked to categorize how serious Fabry disease was for males and for females.  
Possible responses included: 
 
86%
14%
ERT
No ERT
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 Fabry disease is very serious 
 Fabry disease is somewhat serious 
 Fabry disease can be serious, but is not always serious 
 Fabry disease is not serious 
The majority of participants, approximately 91%, indicated that Fabry disease was very serious 
for males.  In contrast, approximately 48% of participants indicated that Fabry disease was very 
serious for females.  For males, approximately 2% of participants indicated that Fabry disease was 
somewhat serious and 7% of participants indicated that Fabry disease could be serious, but was 
not always serious.  For females, approximately 18% of participants indicated that Fabry disease 
was somewhat serious, and 34% of participants indicated that Fabry disease could be serious, but 
was not always serious. The p-value for this analysis was adjusted using the Bonferroni correction 
to a value of 0.02.  Differences between the perceived severity for males and females were 
statistically significant as calculated by both the Friedman test (p-value of 7.74e-6) and the 
Wilcoxon test (p-value less than 2.2e-16). No participants (0%) indicated that Fabry disease was 
not serious for males or for females (Figure 7). 
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Figure 7. Characterization of perceived severity of Fabry disease for males compared to females 
(N=44) 
3.2.2 Degree of worry about Fabry disease 
Participants were asked to characterize the amount of worry they felt regarding Fabry disease.  
Possible responses included: 
 I am very worried about Fabry disease 
 I am somewhat worried about Fabry disease 
 I am worried very little about Fabry disease 
 I am not worried about Fabry disease 
Approximately 46% of participants indicated they were very worried about Fabry disease, 41% 
indicated that they were somewhat worried about Fabry disease, 7% indicated they were worried 
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very little about Fabry disease, and 7% indicated that they were not worried about Fabry disease 
(Table 7). 
Table 7. Characterization of degree of worry about Fabry disease (N=44) 
Degree of worry Percentage indicated by subjects 
Very worried 45.5% 
Somewhat worried 40.9% 
Worried very little 6.8% 
Not worried 6.8% 
 
 Participants who indicated they were worried about Fabry disease were asked to describe 
what worried them the most in a free response format.  Of the 41 participants who indicated they 
had some degree of worry regarding Fabry disease, four participants did not respond to this 
question.  Thematic analysis was performed on the remaining 39 responses to determine themes 
regarding topics of worry (Table 8).   
 One of the themes identified was uncertainty.  Participants expressed concern regarding 
the inability to predict the development of symptoms for relatives or for themselves, whether or 
not their children would inherit Fabry disease, and the availability of treatment and management 
in the future.  One participant described her worry about the future: 
Not knowing what my children and I may have to face in the future.  Doctors do not know a lot 
about Fabry.  I also worry about Health Coverage in the future.   
Another participant writes how she worries about the possibility of passing on Fabry disease to 
other family members: 
I’m worried that I passed this on to my daughter and thus, perhaps, to my 2 grandsons. 
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 A theme of concern for disease impact on children was noted in the responses.  Participants 
expressed worry regarding children’s quality of life.  One participant discussed her worry 
regarding her son and his diagnosis of Fabry disease: 
I am not worried about my Fabry disease as I have few symptoms.  I worry more about my son 
who is diagnosed with Fabry’s disease.  It affects him more than me. 
 
 Another theme identified was premature death.  Participants expressed this worry in regard 
to their own lifespans and in regard to relatives as well.  One participant wrote regarding her own 
lifespan: 
I worry that my life will be cut short.  I won’t get to do the things I want. 
 
 An additional theme identified regarding worry was the inevitability of disease 
progression.  Participants were concerned about the development of more severe symptoms of 
Fabry disease including renal failure, stroke, and heart disease.  A participant explained her 
concern about the development of more serious disease complications: 
Worry about long term symptoms of disease like heart issues or kidney issues 
 
 The final theme identified within the responses with regard to worry was cost, specifically 
regarding disease treatment and management.  One participant described cost as her greatest source 
of worry: 
I worry about health care coverage and continuing to pay for treatment. 
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Table 8. Themes from aspects of Fabry disease most worried about (N=39) 
Themes for analysis Featured topics 
 
Uncertainty 
Development of symptoms  
-For relatives 
-For self 
Inheritance/risk for children 
Availability of treatment/management 
Concern for disease impact on children Quality of life 
Premature death Self 
Relatives 
Disease progression Resulting burden 
Cost Treatment 
Management 
 
3.3 SPECIFIC AIM THREE 
3.3.1 Perceived susceptibility 
Participants were asked to indicate what symptoms Fabry disease can cause in males and females.   
Fabry disease symptoms were listed in a table (Table 9).  Participants could indicate a symptom 
caused by Fabry disease by checking a box next to the symptom in question.  Participants were 
then asked to indicate what symptoms of Fabry disease they had and what symptoms they thought 
they were likely to develop in two separate tables.  These responses were combined for analysis to 
represent symptoms participants’ had and/or felt they were likely to develop. Questions were 
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intended to characterize the perceived susceptibility of males with Fabry disease, females with 
Fabry disease, and participants’ perceived personal susceptibility to Fabry disease symptoms 
(Table 10). 
Table 9. Symptoms of Fabry disease 
Proteinuria (excess protein in the urine) Kidney failure                                     
Congestive heart failure (heart cannot pump 
enough blood to meet the body’s needs) 
Heart attack                                          
Enlargement of heart Abnormal heart rhythm (irregular heart beat) 
Stroke Transient ischemic attack (mini-stroke)                                  
Chronic pain Burning/numbness/tingling in hands or feet 
Heat and/or cold intolerance Problems with sweating                                   
Abdominal pain  Diarrhea and/or constipation                                     
Angiokeratomas (clustered red skin 
markings) 
Corneal whorls (pattern on transparent area of 
eye only visible by slit lamp exam) 
Pulmonary (lung) disease Depression and/or anxiety 
 
Table 10. Means of characterization of Fabry disease susceptibility for males, females, and participants  
Question  Intent to characterize 
Based on your understanding, what symptoms 
can Fabry disease cause in males? 
Susceptibility of males to Fabry disease 
symptoms 
Based on your understanding, what symptoms 
can Fabry disease cause in females? 
Susceptibility of females to Fabry disease 
symptoms 
What symptoms of Fabry disease, if any, do 
you have? 
 
Participant-susceptibility to Fabry disease 
symptoms What symptoms of Fabry disease, if any, do 
you feel you are likely to develop? 
 
In males, the percentage of symptoms participants indicated that could be caused by 
Fabry disease (male susceptibility) were as follows: proteinuria (91%), congestive heart failure 
(66%), enlargement of heart (68%), stroke (89%), chronic pain (95%), heat/cold intolerance 
(98%), abdominal pain (86%), angiokeratomas (100%), pulmonary disease (50%), kidney failure 
(95%), heart attack (80%), abnormal heart rhythm (73%), TIA (80%), burning/numbness/tingling 
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(100%), problems with sweating (93%), diarrhea/constipation (93%), corneal whorls (93%), and 
depression/anxiety (89%) (Table 11). 
In females, the percentage of symptoms participants’ indicated that could be caused by 
Fabry disease (female susceptibility) were as follows: proteinuria (91%), congestive heart failure 
(64%), enlargement of heart (64%), stroke (84%), chronic pain (86%), heat/cold intolerance 
(91%), abdominal pain (89%), angiokeratomas (89%), pulmonary disease (43%), kidney failure 
(86%), heart attack (77%), abnormal heart rhythm (77%), TIA (77%), burning/numbness/tingling 
(96%), problems with sweating (91%), diarrhea/constipation (91%), corneal whorls (96%), and 
depression/anxiety (86%) (Table 11). 
The percentage of symptoms participants’ indicated that they had and/or were likely to 
develop (personal susceptibility) were as follows: proteinuria (64%), congestive heart failure 
(21%), enlargement of heart (23%), stroke (37%), chronic pain (43%), heat/cold intolerance 
(71%), abdominal pain (39%), angiokeratomas (50%), pulmonary disease (19%), kidney failure 
(43%), heart attack (39%), abnormal heart rhythm (52%), TIA (39%), burning/numbness/tingling 
(75%), problems with sweating (43%), diarrhea/constipation (59%), corneal whorls (68%), and 
depression/anxiety (50%) (Table 11). 
Analysis using McNemar’s test of homogeneity was performed in order to characterize 
the perceived susceptibility of females with Fabry disease compared to the perceived personal 
susceptibility of participants.  The p-value for this analysis was adjusted using the Bonferroni 
correction to a value of 0.003.  Statistical significance was observed for symptoms of Fabry 
disease including proteinuria, congestive heart failure, enlargement of heart, stroke, chronic pain, 
heat/cold intolerance, abdominal pain, angiokeratomas, pulmonary disease, kidney failure, heart 
attack, abnormal heart rhythm, TIA, burning/numbness/tingling, problems with sweating, 
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diarrhea/constipation, corneal whorls, and depression/anxiety (Table 13 and Figure 9).  A trend 
was found regarding susceptibility to the following symptoms: heat/cold intolerance (p-value of 
0.0268), pulmonary disease (p-value of 0.0098), abnormal heart rhythm (p-value of 0.0162), 
burning/numbness/tingling (p-value of 0.0133), and diarrhea/constipation (p-value of 0.0059).  
However, using the adjusted p-value of 0.003 these analyses were determined to be statistically 
insignificant.  All of the symptoms, regardless of statistical significance, were selected with 
greater frequency for females with Fabry disease than for the participants’ personally (Table 12).   
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Table 11. Percentage of symptoms caused by Fabry disease for males, females and for participants personally 
(N=44) 
Symptoms Males Females Participants 
Proteinuria 90.91% 90.91% 63.64% 
Congestive heart failure 65.91% 63.64% 20.45% 
Enlargement of heart 68.18% 63.64% 22.73% 
Stroke 88.64% 84.09% 38.64% 
Chronic pain 95.45% 86.36% 43.18% 
Heat/cold intolerance 97.73% 90.91% 70.45% 
Abdominal pain 86.36% 88.64% 38.64% 
Angiokeratomas 100.00% 88.64% 50.00% 
Pulmonary disease 50.00% 43.18% 18.18% 
Kidney failure 95.45% 86.36% 43.18% 
Heart attack 79.55% 77.27% 38.64% 
Abnormal heart rhythm 72.73% 77.27% 52.27% 
TIA 79.55% 77.27% 38.64% 
Burning/numbness/tingling 100.00% 95.45% 75.00% 
Problems with sweating 93.18% 90.91% 43.18% 
Diarrhea/constipation 93.18% 90.91% 59.09% 
Corneal whorls 93.18% 95.45% 68.18% 
Depression/anxiety 88.64% 86.36% 50.00% 
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Table 12. McNemar’s test of homogeneity analysis of perceived susceptibility of females with Fabry disease 
compared to perceived personal susceptibility of participants (N=44) 
 
Symptoms 
 
Females 
 
Personal 
McNemar’s 
chi-squared 
Degrees 
of 
freedom 
 
p-value 
Proteinuria 90.91% 63.64% 10.0833 1 0.0015* 
Congestive heart failure 63.64% 20.45% 17.0526 1 3.64E-5* 
Enlargement of heart 63.64% 22.73% 15.0588 1 0.0001* 
Stroke 84.09% 38.64% 17.0526 1 3.64E-5* 
Chronic pain 86.36% 43.18% 16.0556 1 6.15E-5* 
Heat/cold intolerance 90.91% 70.45% 4.9 1 0.0269 
Abdominal pain 88.64% 38.64% 19.0476 1 1.28E-5* 
Angiokeratomas 88.64% 50.00% 13.4737 1 0.0002* 
Pulmonary disease 43.18% 18.18% 6.6667 1 0.0098 
Kidney failure 86.36% 43.18% 15.4286 1 8.57E-5* 
Heart attack 77.27% 38.64% 15.0588 1 0.0001* 
Abnormal heart rhythm 77.27% 52.27% 5.7857 1 0.0162 
TIA 77.27% 38.64% 13.4737 1 0.0002* 
Burning/numbness/tingling 95.45% 75.00% 6.125 1 0.0133 
Problems with sweating 90.91% 43.18% 18.05 1 2.15E-5* 
Diarrhea/constipation 90.91% 59.09% 7.5789 1 0.0059 
Corneal whorls 95.45% 68.18% 10.0833 1 0.0015* 
Depression/anxiety 86.36% 50.00% 12.5 1 0.0004* 
*p-value<0.003 is statistically significant 
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 Figure 8. Perceived susceptibility of females to Fabry disease symptoms compared to perceived 
personal susceptibility (N=44) 
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3.3.2 Assessment of “carrier” terminology 
In an attempt to characterize the usage and perceived appropriateness of the term “carrier” in 
regard to females diagnosed with Fabry disease, participants were asked the following questions 
in a yes or not format: 
 Have you ever used the word “carrier” to describe yourself? 
 Have any of your physicians or health care providers used the word “carrier” to describe 
your diagnosis? 
 Do you think this term is appropriate? 
The term “carrier” was not defined for participants.  Approximately 66% of participants have used 
the word “carrier” to describe themselves.  Of note, four of the 29 participants who indicated they 
have used the term “carrier” to describe themselves justified this response by explaining they had 
only used the term in the past or currently try not to use the term.   These justifications were not 
asked for, but were written in the margins of the questionnaires.  Approximately 77% of 
participants indicated that a physician or healthcare provider had described them as a “carrier”. 
One participant marked both “yes” and “no” in her response to the question “Do you think this 
term is appropriate”.  Her response was not used in the analysis of the perceived appropriateness 
of the term “carrier”.  Of the 43 remaining participants, approximately 40% of participants 
indicated they believed the term “carrier” was appropriate (Figure 10). 
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Figure 9. Usage and perceived appropriateness of the term “carrier”  
 
Participants were asked to explain why they believed the term “carrier” was either 
appropriate or inappropriate in a free response format.  Thematic analysis was used to determine 
common themes among participants who thought the term “carrier” was appropriate and among 
participants who thought the term “carrier” was inappropriate (Table 13). 
 Of the 17 participants that indicated they believed that the term “carrier” was an 
appropriate description of themselves, one participant did not describe why she thought the term 
carrier was appropriate.  Thematic analysis was completed on the remaining 16 participants’ 
responses.  Overall, participants felt that the term “carrier” indicated the capability to pass the 
disease on, regardless of whether or not the participants had disease symptoms.  One participant 
who described the term “carrier” as appropriate wrote: 
I have symptoms but I also “carry” it/pass it on. 
0%
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 Of the 26 participants that indicated they did not believe the term “carrier” was an 
appropriate description of themselves, two participants did not describe why they thought the 
term was inappropriate.  Thematic analysis was completed on the remaining 24 participants’ 
responses.  In general, participants felt the term “carrier” diminished the amount and/or severity 
of symptoms of Fabry disease a female can have.  A participant who described the term as 
inappropriate wrote: 
Women can experience the same symptoms and be as severely affected 
 
Table 13. Themes from participants who identify the term “carrier” as appropriate and inappropriate 
 Percent of 
participants 
Theme 
 
Appropriate  
 
40% 
 
(N=44) 
Ability to pass on disease, regardless of 
symptoms 
 (N=17) 
 
Inappropriate 
 
60% 
 
(N=44) 
Diminishment of amount /severity of 
symptoms a female can have 
(N=24) 
 
3.4 SPECIFIC AIM FOUR 
3.4.1 Perceived benefits of treatment, evaluation and monitoring 
Participants were asked if they were currently receiving ERT in the treatment of their Fabry 
disease.  Approximately 57% of participants were currently taking ERT (Figure 11).  Participants 
currently on ERT (25 total) were then asked to describe in an open-ended question what their 
expectations of ERT were and how ERT did or did not meet their expectations.  Of the 25 
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participants who were on ERT, 24 provided responses regarding their expectations of ERT.  
Expectations of ERT provided by participants included: improve symptoms (specifically 
gastrointestinal, pain, acroparasthesias, proteinuria, and sweating), prolong life, prevent symptoms 
(specifically organ damage and stroke), stabilize symptoms (specifically renal and cardiac), 
enhance energy, feel better, and lose weight.  One participant indicated she did not have 
expectations for ERT (Table 14). It was not possible to discern whether the expectations listed by 
the aforementioned 24 participants were met using the responses provided by participants in the 
open-ended question, as not all responses were relevant to the specific question asked.  However, 
it was possible to determine if participants had a positive or negative experience with ERT from 
the responses using thematic analysis.  These categorizations were designated in an attempt to 
categorize participant satisfaction with ERT.  Analysis was based on participant word choice.  For 
example, participants’ found to have a positive experience used words that were positive in nature 
when describing their experience with ERT such as “improved”, “better”, “exceeded”, and 
“helped”.  Participants’ found to have a negative experience used words that were negative in 
nature when describing their experience with ERT such as “no”, “cannot”, “sick”, “worse”, and 
“frustrating”. Approximately 49% of participants on ERT had a positive experience and 37% of 
participants on ERT had a negative experience (Figure 12).  About 14% of participants currently 
receiving ERT did not fit into either the positive or negative category based on their language used 
in description of their experience with ERT.  These participants used the phrase “not sure” or used 
a combination of  words that were both positive and negative in nature when describing ERT, 
suggesting that they were grappling with their experience with ERT.  
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Figure 10. Percentage of participants currently receiving ERT  
 
Table 14. Expectations of ERT 
Improve symptoms Prevent symptoms 
Prolong life Stabilize symptoms 
Feel better More energy 
Lose weight None 
 
57%
43%
Currently receiving ERT
Not currently receiving ERT
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Figure 11. Characterization of experience with ERT (N=24)  
3.5 SPECIFIC AIM FIVE 
3.5.1 Perceived barriers to treatment, evaluation and monitoring 
A table of potential barriers to evaluation and monitoring was provided to participants within the 
questionnaire.  Participants were asked to mark what barriers, if any, prevented them from 
participating in monitoring and evaluations.  Participants were also asked in an open-ended 
question to elaborate on barriers they marked in the table or to list additional barriers not provided.  
Approximately 64% participants indicated they felt at least one barrier to evaluation either 
provided in the table or written in the open-ended question section (Figure 13).  Of the barriers 
provided in the questionnaire, the most common barrier indicated was costs not covered by 
49%
37%
14%
Positive
Negative
Unsure
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insurance (36%), followed by distance from centers (30%), and anxiety (25%) (Table 15).  Barriers 
listed by participants that were not included in the provided table included: age (this was not further 
specified by participants), apathy, denial, avoidance of perceived pressure for ERT, and additional 
unrelated to Fabry disease health concerns (i.e. family history of dementia) (Table 16).  
Participants elaborated about costs not covered by insurance.  Participants described that the costs 
of non-ERT prescriptions, copays, high deductibles, and examinations and evaluations not covered 
by insurance prevented them from completing recommended evaluations (Table 17). 
 
Figure 12. Percentage of participants with and without barriers to evaluations and monitoring 
 
 
 
 
 
64%
36%
1 or more barriers indicated
No barriers indicated
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Table 15. Barriers to treatment, evaluation and monitoring (N=44) 
Barriers Percentage indicated by participants 
Costs not covered by insurance 36.36% 
Distance from centers 29.55% 
Anxiety 25.00% 
Feeling overwhelmed 20.45% 
Desire to keep focus on more severely affected family 18.18% 
Symptoms not severe 15.91% 
Frustration with amount of recommended tests 15.91% 
Time 15.91% 
Frustration with lack of provider knowledge 13.64% 
Care of family member affected with Fabry disease 13.64% 
Worry 11.36% 
Difficulties obtaining transportation 11.36% 
Fear of testing 9.09% 
Depression 9.09% 
Insurance/work discrimination 9.09% 
Lack of insurance 9.09% 
Job responsibilities 6.82% 
Childcare responsibilities 6.82% 
Sadness 6.82% 
Lack of support/encouragement 6.82% 
Anger about diagnosis 6.82% 
Poor Health 6.82% 
Not enough info 4.55% 
Feeling undeserving of care/attention 2.27% 
Concern about test results 2.27% 
Guilt 2.27% 
 
Table 16. Additional barriers listed by participants 
Age 
Apathy 
Denial 
Perceived pressure for ERT 
Additional, unrelated to Fabry disease health concerns  
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Table 17. Costs not covered by insurance described by participants 
Prescriptions unrelated to ERT Copays 
High deductibles Examinations and evaluations 
 
3.6 SPECIFIC AIM SIX 
3.6.1 Modifying variables and cues to action: completion of recommended evaluations  
Participants were asked to indicate what evaluations had been recommended to them throughout 
the care of their Fabry disease.  Evaluations were listed in a table (Table 18).  Participants could 
indicate an evaluation had been recommended to them by checking a box next to the evaluation in 
question.  One participant did not respond consistently across questions regarding evaluations so 
her responses were excluded from analysis, leaving a total of 43 participants for analysis.  In the 
care of their Fabry disease, the percentage of evaluations recommended to participants were as 
follows: electrocardiogram (95%), echocardiogram (93%), brain MRI (86%), lipid panel (86%), 
24-hour urine test (81%), GL3 testing (81%), Fabrazyme antibody (65%), heart MRI (49%), slit 
lamp eye exam (49%), audiologic evaluation (44%), 24-hour holter monitor (42%), pulmonary 
function test (33%), and kidney biopsy (19%) (Table 19).   
Participants were also asked to indicate which evaluations they had completed at diagnosis 
and which evaluations they continued to perform on a regular basis using the table format 
described above. The percentage of recommended evaluations that were completed at the time of 
diagnosis and on a regular basis were calculated.  Only participants who had been recommended 
a certain test were included in these calculations.  Of the 35 participants who were recommended 
 54 
to have a 24-hour urine test, 74% had the evaluation done at their time of diagnosis and 57% have 
the evaluation done regularly.   Of the 41 participants who were recommended to have an 
electrocardiogram, 63% had the evaluation done at their time of diagnosis and 68% have the 
evaluation done regularly. Of the 18 participants who were recommended to have a 24-hour holter 
monitor, 39% had the evaluation done at their time of diagnosis and 33% have the evaluation done 
regularly.  Of the 19 participants who were recommended to have an audiologic evaluation, 58% 
had the evaluation done at their time of diagnosis and 26% have the evaluation done regularly.  Of 
the 37 participants who were recommended to have a brain MRI, 65% had the evaluation done at 
their time of diagnosis and 32% have the evaluation done regularly. Of the 28 participants who 
were recommended to have a Fabrazyme antibody, 57% had the evaluation done at their time of 
diagnosis and 46% have the evaluation done regularly. Of the 37 participants who were 
recommended to have a lipid panel, 65% had the evaluation done at their time of diagnosis and 
89% have the evaluation done regularly. Of the 8 participants who were recommended to have a 
kidney biopsy, 63% had the evaluation done at their time of diagnosis and 25% have the evaluation 
done regularly. Of the 40 participants who were recommended to have an echocardiogram, 70% 
had the evaluation done at their time of diagnosis and 73% have the evaluation done regularly. Of 
the 21 participants who were recommended to have a heart MRI, 52% had the evaluation done at 
their time of diagnosis and 33% have the evaluation done regularly.   Of the 14 participants who 
were recommended to have a pulmonary function test, 50% had the evaluation done at their time 
of diagnosis and 50% have the evaluation done regularly. Of the 21 participants who were 
recommended to have a slit lamp eye exam, 62% had the evaluation done at their time of diagnosis 
and 38% have the evaluation done regularly. Of the 35 participants who were recommended to 
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have a GL3 testing, 77% had the evaluation done at their time of diagnosis and 51% have the 
evaluation done regularly (Figure 14). 
In order to calculate whether a recommended evaluation had been completed at any time 
in the care of a participant’s Fabry disease, responses from evaluations completed at the time of 
diagnosis and evaluations that were completed on a regular basis were combined to represent a 
binary response system (completed at any point in time and never completed). McNemar’s test of 
homogeneity was used to determine if there was a statistically significant difference between the 
proportions of participants that were recommended to undergo an evaluation compared to the 
proportion of patients who completed the evaluation. The p-value for this analysis was adjusted 
using the Bonferroni correction to a value of 0.004.  Individual p-values for each evaluation were 
corrected for one-sided analysis. A trend was found for the completion of the following 
recommended evaluations: 24-hour holter monitor (p-value of 0.0079), brain MRI (p-value of 
0.0067), Fabrazyme antibody (p-value of 0.0228), and heart MRI (p-value of 0.0352).  However, 
using the adjusted p-value of 0.004 these analyses were determined to be statistically insignificant. 
Of note, for these evaluations a higher number of evaluations were recommended to participants 
than were completed (Table 20). 
Table 18. Evaluations for Fabry disease 
24 hour urine test (test for kidney function) Renal (kidney) biopsy  
Electrocardiogram/EKG (records heart’s 
electrical activity using electrodes) 
Echocardiogram (ultrasound of the heart) 
24 hour holter heart monitoring (cardiac event 
monitoring) 
Heart MRI (uses magnets to create a picture 
of the heart) 
Audiologic (hearing) evaluation  Pulmonary (lung) function test (breathing 
test) 
Brain MRI (uses magnets to create a picture 
of the brain) 
Slit Lamp eye exam  
Fabrazyme antibody testing (blood test) GL-3 testing (blood or urine test) 
Lipid panel (cholesterol blood test)  
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Table 19. Percentage of evaluations recommended to participants (N=43) 
Evaluation Percentage recommended to participants 
Electrocardiogram 95.35% 
Echocardiogram 93.02% 
Brain MRI 86.05% 
Lipid panel 86.05% 
24 hour urine test 81.40% 
GL-3 testing 81.40% 
Fabrazyme antibody 65.12% 
Heart MRI 48.84% 
Slit lamp exam 48.84% 
Audiologic evaluation 44.19% 
24 hour holter monitor 41.86% 
Pulmonary function test 32.56% 
Kidney biopsy 18.60% 
 
 
Figure 13. Comparison of completion of recommended evaluations at time of diagnosis and 
continued on a regular basis  
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Table 20. McNemar’s test of homogeneity analysis for completion of recommended evaluations 
 
Evaluation 
Number of 
participants indicated 
evaluation 
recommended (N) 
Percent of 
evaluations 
completed at 
any time 
 
McNemar’s 
chi-squared 
 
Degrees 
of 
freedom 
 
p-value 
24-hour holter 
monitor 
18 50% 5.8182 1 
 
0.0079 
Brain MRI 37 76% 6.125 1 0.0067 
Fabrazyme 
antibody 
28 75% 4 1 0.0228 
Heart MRI 21 62% 1.4545 1 0.0352 
*p-value<0.004 is statistically significant 
 
(a) Impact of perceived severity and worry 
Regression analysis was performed to determine if perceived severity or worry impacted the 
completion of recommended evaluations. Only participants who reported a given recommended 
evaluation were included in analysis. The p-value for this analysis was adjusted using the 
Bonferroni correction to a value of 0.004.  Analyses failed to identify a statistically significant 
relationship between perceived severity or worry and completion of recommended evaluations. 
(b) Impact of perceived susceptibility 
Analysis using Fisher’s exact test was performed to determine if perceived personal susceptibility 
to Fabry disease symptoms impacted the completion of recommended evaluations.  Only 
participants who reported a given recommended evaluation were included in analysis. Perceived 
susceptibility for each Fabry disease symptom (18 total symptoms) was compared to completion 
of each evaluation recommended to a participant (13 total evaluations) and assessed for statistical 
significance (234 combinations).  The p-value for this analysis was adjusted using the Bonferroni 
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correction to a value of 0.0002.  Analyses failed to identify a relationship of statistical significance 
between perceived susceptibility and completion of recommended evaluations. 
Analysis using Fisher’s exact test was also performed to determine if the presence of 
specific symptoms at the time of diagnosis affected the completion of recommended evaluations. 
The adjusted p-value of 0.0002 described above was used in this analysis.  Analyses failed to 
identify a statistically significant association between specific symptoms at diagnosis and 
completion of recommended evaluations. 
3.6.2 Modifying variables: impact of a diagnosis of Fabry disease 
All participants (100%) reported a diagnosis of Fabry disease.  A diagnosis of Fabry disease was 
defined as “by genetic testing or family history alone”.   
3.6.2.1 Characterization of feelings about and reactions to diagnosis 
Participants were asked in an open-ended question to explain how they felt after receiving a 
diagnosis of Fabry disease (Table 21 for list of themes identified within responses).  The theme of 
concern for children and other relatives was identified within the responses.  Emotions connected 
to the theme of concern for children included sadness, depression/hopelessness, and fear.  One 
participant wrote with regard to her diagnosis: 
It was sad that I might have passed this on to my children 
Another participant expressed fear for her children to inherit Fabry disease: 
Fear I had passed it to one of my three children 
While most of the responses eluded to feelings of guilt regarding their children’s inheritance of 
Fabry disease, only one participant self-identified the feeling of guilt associated with her diagnosis. 
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Guilty.  The mutation started with me and I passed it on to my daughter.  She was diagnosed 
first.  Then I was found to have it. 
 
The theme of concern for self was also identified in the responses.  These responses were 
permeated with a sense or foreboding or dread, sadness, and fear.  A participant expressed feelings 
of excessive sadness and worry with regard to her diagnosis: 
Very depressed and stressed.  Saw what my dad went through and died young- 52 yrs old. 
 
Another theme identified in the responses was validation.  Participants expressed a sense 
of relief in learning that their symptoms were not imagined or for finding an explanation for their 
symptoms.  One participant wrote: 
Understood what was causing the symptoms that I always had. (Like not sweating.) 
Additionally, participants appreciated finding the explanation for their relatives’ unexplained 
symptoms or deaths. A participant expressed a sense of relief that she had learned the reason that 
her father passed away: 
Relieved to finally know what killed my father in 1964 and relieved to be treated before its too 
late in my case. 
 
Overall, the themes of validation, concern for children and other relatives, and concern for 
self were often expressed simultaneously.  An example of a response with a combination of the 
themes of validation and concern for self is shown below: 
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Relieved I wasn’t “making up” and going crazy with symptoms that began when I was 16 years 
old.  It also put me in a depressed state knowing what would happen to me medically.  Seeing my 
mom being sick and dying with the Fabry was a major reality check. 
Another participant expressed the themes of concern for self and concern for children and other 
relatives when she wrote: 
It was very upsetting.  I was afraid for my own health and the health of any children I might 
have. 
 
Finally, a theme of indifference and/or delayed reaction was identified within the responses 
of ten participants.  These participants elaborated regarding the sources of their indifference.  
Explanations for indifference included: young age at diagnosis (either led to a normalization of 
Fabry disease or inability to understand implications), labeled as a carrier (misunderstanding that 
not at risk for disease complications), and an assumption of diagnosis (expected a diagnosis of 
Fabry disease prior to diagnosis).  One participant explained her perspective: 
My diagnosis came when I was only 14 y/o.  At that time, “only a carrier” was used to describe 
me.  Therefore, I didn’t give it much thought until older- even though I was symptomatic. 
Another participant demonstrated her indifference due to her assumed diagnosis: 
Already knew I had it. 0 change (Δ). 
Another participant explained the normalization of diagnosis for both her and her sister, 
attributing this phenomenon to the age of diagnosis: 
I was 5, this has always been a part of my life.  For me this is my normal, my sister was born a 
year after we found out so she has known all her life. 
Another participant explained how the age of her diagnosis impacted her reaction: 
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I was young (11 years old) and remember being indifferent/not fully understanding.  It wasn’t 
until I became an adult, responsible for my own health decisions that I realized the seriousness. 
Table 21. Themes from feelings and reactions to diagnosis (N=44) 
Themes from analysis Contributing emotions 
 
 
Concern for children and other relatives 
Excessive sadness 
Fear 
Guilt 
 
 
Concern for self 
Dread/sense of foreboding 
Excessive sadness 
Fear 
Validation Relief 
 
 
Indifference and/or delayed reaction 
 
Diagnosis at young age 
-Normalization 
-Inability to comprehend implications 
Labeled as “carrier” 
-Believed not at-risk for disease symptoms 
Assumed/expected diagnosis 
 
In addition to these themes, emotions including anger, hyperawareness of symptoms and 
surprise were described. 
 
3.6.2.2 Impact of diagnosis on ideas about health 
Approximately 75% of participants indicated that a diagnosis of Fabry disease impacted their ideas 
about their health (Figure 15).   
 62 
 
Figure 14. Proportion of participants with health ideas impacted by diagnosis of Fabry disease 
(N=44) 
Participants who indicated a change in health beliefs were asked to explain how their ideas 
about their health were impacted in an open-ended question.  Of the 33 participants who indicated 
that a diagnosis of Fabry disease impacted their health beliefs, five participants did not complete 
the question and two participants provided responses that did not expand or explain how a 
diagnosis of Fabry disease impacted their ideas about their health.  Thematic analysis was utilized 
to identify patterns or themes in the 26 remaining responses (Table 22).   
A theme identified from the responses was hyperawareness of disease symptoms and 
general health issues.  Participants expressed an overall increased sensitivity to health issues and 
Fabry disease symptoms.  A participant explained how her diagnosis of Fabry disease increased 
her awareness of her health: 
More aware if I would have any changes in my health. 
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Another theme identified was a change in health care practices.  Changes in health care 
practices varied from basic changes like improved diet or increased exercise to more extreme 
measures such as pregnancy risk management by tubal ligation.  Participants also discussed how 
the introduction of Fabry disease treatment into their regimen resulted in a change in health beliefs. 
One participant described a change in her health practices: 
I try to eat healthier now.  Try to rest more.  I do worry about my future now. 
One participant described her reproductive decisions due to her diagnosis of Fabry disease: 
Tubal ligation at 21 years old to not take a chance of giving to a child. 
 
Additionally, a theme expressed by participants was a change in perception of health.  
Changes in perception included shortened lifespan, reduced quality of life and health, as well as 
an improved understanding of their own health.  A participant expressed how her diagnosis 
affected her self-perception of health. 
I felt like my lifespan was automatically shortened and quality of life reduced. 
Participants also described how learning about Fabry disease improved their understanding of 
their symptoms or family history.  One participant demonstrated how her diagnosis improved her 
understanding of her health: 
I know I became aware of a whole new world and new vocabulary.  But with the developing 
health problems it made sense of what was happening. 
Finally, a theme of increased worry was identified in responses.  Increased worry was 
associated with health insurance and work discrimination, long-term issues, and deterioration of 
health.  One comment written by a participant suggested that she was concerned regarding her 
insurance coverage: 
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There are not many alternative medical treatments to relieve symptoms or long term 
prognosis.  Ability to be insured. 
Another participant described increased worry about long-term health issues: 
Felt like something else medical I had to deal with.  Worried about long term issues. 
A participant described increased worry about her health: 
I became very concerned about my kidney function.  My father died from renal failure. 
Many of the themes identified were expressed simultaneously in participants’ responses.   
This phenomenon can be seen in some of the quotes selected above.  In another example, one 
response demonstrated the themes of change in perception of health, increased worry, and change 
in health care practices. 
The symptoms I have were easy to ignore before.  Now I know they may be a sign of more 
serious problems, so I am much more worried than before.  I keep thinking, that I have to take 
really good care of my self.  
Table 22. Impact of diagnosis on health beliefs (N=26) 
Themes from analysis Components of themes 
Hyperawareness 
Fabry disease symptoms 
General health concerns 
Improved diet 
Increased exercise 
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Change in health care practices Treatment for Fabry disease 
Pregnancy prevention 
Change in perception of health 
Shortened lifespan 
Reduced quality of life and health 
Better understanding of health 
Increased worry 
Insurance/Work discrimination 
Long-term issues 
Deterioration of health 
3.6.3 Modifying variables: participants currently receiving ERT compared to 
participants not currently receiving ERT 
Analyses were performed to identify differences in demographics, perceived severity, perceived 
susceptibility, perceived barriers to treatment evaluation and monitoring, and completion of 
recommended evaluations between participants currently receiving ERT (43%) and participants 
not currently receiving ERT (57%) (See Figure 11).  
3.6.3.1 Demographics 
Analyses failed to identify differences of statistical significance between participants currently 
receiving and not receiving ERT with regard to demographics and family history.  Regression 
analyses were performed for demographic variables including: age, income, educational 
background, employment status, marital status, health care coverage, and inability to see a doctor 
due to cost within the last 12 months.  P-values for these variables were adjusted using the 
Bonferroni correction method for multiple comparisons.  Analyses did not identify statistically 
significant associations with these variables and participants currently receiving or not receiving 
Table 22 Continued
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ERT.  Regression analyses were also performed on variables of family history including whether 
or not a participant had children affected with Fabry disease and the number of relatives a 
participant indicated had Fabry disease.  Analyses did not identify statistically significant 
associations with these variables and participants currently receiving or not receiving ERT. 
3.6.3.2 Perceived severity 
Regression analyses failed to identify differences of statistical significance between participants 
currently receiving ERT and not currently receiving ERT with regard to perceived severity and 
degree of worry.  Regression analysis was used to determine if severity or worry predicted whether 
a participant would be currently receiving or not receiving ERT. Analysis using Fisher’s exact test 
failed to identify a statistically significant association between the use of ERT and impact of health 
beliefs due to diagnosis of Fabry disease.  
3.6.3.3 Perceived susceptibility 
Analysis using Fisher’s exact test was performed to determine if perceived personal susceptibility 
to Fabry disease symptoms was associated with participants currently receiving ERT and not 
currently receiving ERT.  The p-value for this analysis was adjusted using the Bonferroni 
correction to a value of 0.003.  A relationship with statistical significance was identified for 
heat/cold intolerance. A trend was found regarding susceptibility to the following symptoms: 
chronic pain (p-value of 0.006), abdominal pain (p-value of 0.03), burning/numbness/tingling (p-
value of 0.01), and diarrhea/constipation (p-value of 0.03) (Table 24). Participants currently 
receiving ERT were more likely to express personal susceptibility for these five Fabry disease 
symptoms than participants not currently receiving ERT (Figure 15).  Analysis using Fisher’s exact 
test failed to identify differences of statistical significance between participants currently receiving 
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ERT and not currently receiving ERT with regard to the perceived appropriateness of the term 
“carrier”.  
Table 23. Fisher’s exact test analysis for personal susceptibility and current reception of ERT 
Symptoms Odds Ratio 95% CI p-value 
Chronic pain 6.35 (1.44-34.76) 0.006 
Heat/cold intolerance 11.95 (2.00-133.32) 0.002* 
Abdominal pain 4.60 (1.05-24.65) 0.03 
Burning/numbness/tingling 7.93 (1.29-89.12) 0.01 
Diarrhea/constipation 4.19 (1.01-19.40) 0.03 
*p-value<0.003 is statistically significant
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Figure 15. Personal susceptibility to symptoms with a statistically significant difference between 
participants currently and not currently receiving ERT  (N=44) 
3.6.3.4 Perceived barriers to treatment, evaluation and monitoring 
Analysis using Fisher’s exact test failed to identify statistically significant specific barriers to 
Fabry disease evaluations and monitoring that were associated with participants currently 
receiving ERT and not currently receiving ERT.  The p-value for this analysis was adjusted using 
the Bonferroni correction to a value of 0.002.  A trend was identified between participants currently 
receiving and not receiving ERT with regard to the percentage who indicated “symptoms not 
severe” as a barrier (p-value of 0.03) (Table 25).  Participants receiving ERT were less likely to 
indicate “symptoms not severe” than participants not currently receiving ERT (Figure 16). 
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Table 24. Fisher’s exact test analysis for perceived barriers and current reception of ERT 
Barrier Odds Ratio 95% CI p-value 
Symptoms not severe 0.10 (0.002-0.91) 0.03 
*p-value<0.002 is statistically significant 
 
 
 
Figure 16. Percentage of participants currently and not currently receiving ERT   who indicated “symptoms 
not severe” as barrier (N=44) 
3.6.3.5 Completion of recommended evaluations 
Analysis using Fisher’s exact test failed to identify differences of statistical significance between 
participants currently receiving ERT and not currently receiving ERT with regard to the 
completion of recommended evaluations in the care of Fabry disease.   
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3.6.4 Modifying variables: participants who indicated no barriers to evaluations and 
monitoring compared to participants who indicated one or more barriers 
Analyses were performed to identify differences in demographics, perceived severity, perceived 
susceptibility, perceived barriers to treatment evaluation and monitoring, and completion of 
recommended evaluations between participants who indicated they had no barriers to evaluations 
and monitoring (36%) and participants who indicated one or more barrier (64%) (Figure 13).    
3.6.4.1 Demographics 
Regression analyses were performed for demographic variables including: age, income, 
educational background, employment status, marital status, health care coverage, and inability to 
see a doctor due to cost within the last 12 months.  P-values for these variables were adjusted using 
the Bonferroni correction method for multiple comparisons.  The difference between participants 
who did and did not indicate barriers to evaluations and monitoring with regard to the demographic 
variable of household income had a p-value of 0.012 (p-value<0.05), however, the subsequently 
adjusted p-value for this variable of 0.008 resulted in this relationship being determined 
statistically insignificant.  Of note, this calculation demonstrated that participants who indicated 
no barriers to evaluations and monitoring were more likely to have a higher household income 
than individuals who indicated one or more barrier (Table 26). 
Analyses did not identify statistically significant associations with the variables of age, 
educational background, employment status, marital status, health care coverage, and inability to 
see a doctor due to cost within the last 12 months and participants who indicated no barriers to 
evaluations and monitoring and participants who indicated one or more barrier.  Regression 
analysis was also performed on variables of family history including whether or not a participant 
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had children affected with Fabry disease and the number of relatives a participant indicated had 
Fabry disease.  Analysis did not identify statistically significant associations with these variables 
and participants who did and did not indicate barrier to evaluations. 
 
Table 25. Regression analysis for level of household income and participants who did and did not indicate 
barriers to evaluation and monitoring  
Demographic Coefficient Error Z-value p-value 
Household 
income 
0.7310 0.2908 2.514 0.0120 
*p-value<0.008 for statistical significance 
 
3.6.4.2 Perceived severity 
Regression analyses failed to identify differences of statistical significance between participants 
who indicated no barriers to evaluations and monitoring and participants who indicated one or 
more barrier with regard to perceived severity and degree of worry.  Analysis using Fisher’s exact 
test failed to identify a statistically significant association between the presence of self-identified 
barriers to evaluations and monitoring and impact of health beliefs due to diagnosis of Fabry 
disease.   
3.6.4.3 Perceived susceptibility 
Analyses using Fisher’s exact test failed to identify differences of statistical significance between 
participants who indicated no barriers to evaluations and monitoring and participants who 
indicated one or more barrier with regard to perceived personal susceptibility and the perceived 
appropriateness of the term “carrier”.   
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3.6.4.4 Proportion currently receiving ERT 
Analysis using Fisher’s exact test failed to identify statistically significant differences with regard 
to the proportion of participants on ERT between participants who indicated no barriers to 
evaluations and monitoring and participants who indicated one or more barrier to evaluations and 
monitoring.   
3.6.4.5 Completion of recommended evaluations 
Analysis using Fisher’s exact test failed to identify differences of statistical significance with 
regard to the completion of recommended evaluations between participants who indicated no 
barriers to evaluations and monitoring and participants who indicated one or more barrier to 
evaluations and monitoring.   
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4.0  DISCUSSION 
4.1 DEMOGRAPHICS 
This study included the assessment of 44 females over the age of 18 with a diagnosis of Fabry 
disease.  Almost all of the study participants were Caucasian and all participants reported a 
diagnosis of Fabry disease.  The median age of participants was 49 years of age, which was higher 
than the reported median age of females of 38.5 years from the 2012 US Census Bureau data. The 
majority of participants (approximately 71%) had a total household income greater than $35,000 
and approximately 32% of participants reported a total household income greater than $75,000, 
which is comparable to  the median household income reported from the 2012 US Census Bureau 
of $51,071. In general, participants from this study were more educated and a higher percentage 
had health care coverage as compared to the 2012 US Census Bureau data.  The percentages of 
participants who had four years of college (Bachelors degree) and graduate level education 
(Masters or Doctoral degree) were both higher than those reported in the 2012 US Census. In 
addition, the percentage of participants with health care coverage (95%) was higher than the 
average reported from the 2012 US Census Bureau (84%).  A little over half (56%) of participants 
were married as compared to 38% of individuals surveyed by America’s Families and Living 
Arrangements (Table 4).   
To assess the geographic diversity of the study population, participants were localized into 
regions of the United States based on the Fabry disease managing center or clinic they indicated 
on the study questionnaire (Figures 1 and 3 and Table 5). The United States Census Bureau defines 
a region as a grouping of states that subdivides the nation. The participants were localized in the 
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United States by region rather than by state or division to better visualize the sample across the 
nation due to the small size of the study population.  It was theorized that the residences of 
participants were likely within the same region of the United States that their management was 
conducted.  Regions of the United States included the Northeast, South, Midwest, and West 
(Appendix H). The distribution of the localizable participants based on management site was 
relatively evenly spread among the Midwest (32%), South (24%), West (16%), and Northeast 
(15%) (Figure 2).  
Information regarding family history was collected for analysis to assess how family 
history might impact perceived health beliefs and completion of recommended assessments. The 
majority of participants, approximately 98%, reported a family history of Fabry disease (See 
Figure 3), which is consistent with the inheritance of Fabry disease as de novo mutations are rare.59   
The majority of participants, approximately 56%, indicated their Fabry disease was maternally 
inherited (Figure 5).  The most common relative with Fabry disease indicated by participants was 
“mother”, which is consistent with this observation.  Interestingly, the five most common relatives 
(mother, sister, father, son, and daughter) with Fabry disease were all immediate family members 
to the participants (Table 6).  This suggests that at least 47% of participants have witnessed the 
course of Fabry disease in male and/or female relatives with whom they have likely shared a 
residence. Approximately 86% of participants with a family history of Fabry disease had a relative 
who had received ERT (Figure 6).  In comparison, 57% of the total participants within the study 
were personally receiving ERT (Figure 11).  Participants who were not currently receiving ERT 
may have had some degree of familiarity with ERT due to the treatment of a relative. 
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4.2 SPECIFIC AIM ONE 
4.2.1 Administration of survey and questionnaire to 50 females at-risk or diagnosed with 
Fabry disease 
In the aim to recruit 50 female participants this study was unsuccessful.  This was likely due to a 
limitation of the study design in which investigators were unable to directly contact potential 
participants. In addition, issues with follow-up for interested participants also complicated the 
ability to recruit and consent the study aim of 50 participants.  Two participants who contacted the 
PI were unable to be re-contacted for study consent due to issues with follow-up.  These 
participants contacted the PI to participate in the study and when the PI attempted to contact the 
participants, the participants never returned the PI’s phone calls. 
4.3 SPECIFIC AIM TWO 
4.3.1 Characterization of the perceived severity for males and females with Fabry disease 
Participants were asked to categorize the severity of Fabry disease for both males and females 
(Figure 7).  The majority of participants (91%) categorized Fabry disease as very serious for males.  
In contrast, the responses of participants were more varied when asked about the severity of Fabry 
disease for females.  Responses for females included very serious (48%), somewhat serious (18%), 
and can be, but is not always serious (34%).  The diversity of responses for severity in females 
demonstrates the variability of Fabry disease presentation and progression in females as compared 
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to males.6 Additionally, all participants indicated that Fabry disease was associated with some 
degree of severity for both males and females.  The differences in responses with regard to severity 
for males and for females, as well as, the fact that no participants thought Fabry disease was not 
serious for males or female suggests that participants had an appropriate understanding of Fabry 
disease severity that was consistent with current understanding of the medical community.2; 3; 6  
These results suggest that these participants have received appropriate information regarding  the 
variability of Fabry disease for females as compared to males. 
4.3.2 Characterization of the amount and topics of worry regarding Fabry disease 
The majority of participants, approximately 86%, were somewhat to very worried about Fabry 
disease (Table 7).  These results suggest that females with Fabry disease may be significantly 
burdened by worry.  This highlights the need for healthcare providers, such as genetic counselors 
and/or physicians, to investigate what specific worries their female patients might have in order to 
better address concerns and improve patient outcomes.  Thematic analysis was utilized to identify 
themes or patterns regarding topics of worry written in response to the open-ended question (Table 
8).  Many of the topics of worry identified in this analysis are concerns that are able to be addressed 
or reduced by healthcare providers.  Strategies to manage specific concerns of females with Fabry 
disease are discussed below  to provide ways for healthcare providers to reduce the burden of 
worry for their female patients, potentially improving rapport and communication between patients 
and providers.  In addition, reduction of worry for female patients may reduce barriers to 
evaluation and treatment for females who are significantly burdened by worry.   
Within the responses to the open-ended question, a theme of uncertainty was identified, 
specifically with regard to symptom development, inheritance, and availability of treatment and 
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management.  Worry due to the uncertainty of symptom development extended to the participant’s 
relatives, as well as the participant herself.  This theme further demonstrates an appropriate 
understanding of the variable presentation and course of Fabry disease for females that was 
previously noted in assessment of perceived severity.6  This variability of disease progression in 
females and family members, as well as the absence of genotype-phenotype correlation data 
present challenges to healthcare providers attempting to describe an accurate disease course for 
females with a GLA mutation.6  While healthcare providers are limited in their ability to reduce 
the uncertainty associated with a Fabry disease diagnosis, acknowledgement of this burden may 
help healthcare providers to better build rapport with their female patients. 
In addition to uncertainty of disease progression, analysis demonstrated that the uncertainty 
associated with potentially passing on Fabry disease to subsequent generations in an individual’s 
family was a source of worry for participants.  Discussions regarding current prenatal options to 
prevent the transmission of a gene mutation to a future family member such as chorionic villi 
sampling, amniocentesis or pre-implantation genetic diagnosis may help to manage anxiety 
regarding the uncertain nature of potentially passing on a GLA mutation. Discussion of prenatal 
options are recommended for both males and females with Fabry disease of reproductive age24; 
however, acknowledgement of these options may also benefit post-menopausal females worried 
about risks for grandchildren.  Recent evidence suggests that a diagnosis of an X-linked condition, 
like Fabry disease, can have profound and lasting effects on extended family, particularly on 
grandmothers, who may also benefit from educational measures and genetic counseling.60 In 
addition, education has been associated with increased perceived personal control, defined as “the 
belief that one has at one’s disposal a response that can influence the aversiveness of the event”.61; 
62 Perceived personal control has been implicated as a central means to cope with health threats 
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including chronic genetic conditions.61  The promotion of perceived personal control may be 
particularly effective in addressing this concern of inheritance, as the underlying issue is 
uncertainty. Education from healthcare providers about risks for family members to have a GLA 
mutation based on X-linked inheritance and about the availability of future treatment options for 
potentially affected family members may be helpful in decreasing this worry by promoting 
perceived personal control.   
Finally, uncertainty regarding the future availability of treatment and management was also 
a source of worry for participants.  Concerns with regard to treatment and management availability 
were largely tied to the uncertainty of insurance coverage.  Gibas et al. 2008 suggested that genetic 
counselors can play a role as advocates for females with Fabry disease and this advocacy can 
include addressing client concerns related to healthcare coverage.9  Advocacy by genetic 
counselors or other healthcare providers may not eliminate this worry, but may prevent or lessen 
the fear of treatment or management unavailability from being realized. 
Another theme identified as a source of worry was premature death.  This theme is similar 
to the awareness of shortened lifespan identified by Kolodny et al. (2002) that contributes to poor 
quality of life for Fabry disease patients.29 Females are at risk to develop life threatening 
complications of Fabry disease such as renal failure, stroke, and cardiac complications that could 
lead to premature death.5; 6; 33 While current literature suggests that the lifespans of females are 
minimally shortened when compared to males, variability of disease symptomology limits the 
degree of reassurance a health care provider can offer to an individual.6; 32 Clarification of the 
individual’s perception of her lifespan may help to address their concerns and recognize when 
additional therapeutic support should be offered.  Also, it is the opinion of this investigator that 
family history of the individual may act as a modifying variable for the worry of premature death.  
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The premature deaths of parents, brothers, or other relatives were mentioned throughout the 
responses of participants in the questionnaires.  Clarification of disease progression for males 
compared to females may help to alleviate this worry for participants whose concern relates to the 
premature death of a male relative.  In addition, the discussion of the variability of disease for 
females could be utilized as an approach to offer support for females whose concern stems from 
the premature death of a female relative and a sense of inevitability for their own shortened 
lifespan.  With regard to worry associated with the premature deaths of relatives, disease variability 
within families and for females in general may still act as a barrier for healthcare providers to 
address this concern for their female patients.6; 22-24  Healthcare providers should initiate 
conversations with their female patients who express concern for the premature death of one or 
more relatives to assess whether or not their patients would benefit from therapeutic measures such 
as support groups or individual therapy. 
Additional themes identified in thematic analysis of worry were cost, concern for disease 
impact on children, and disease progression. Concerns regarding cost were seen throughout 
analyses in this study and will be discussed further with regard to barriers to treatment, evaluation, 
and management.  Analysis from this study delineates the importance of financial assistance for 
individuals and families with Fabry disease.  The theme of concern for disease impact on children 
was identified as a source of worry for participants, specifically regarding quality of life for their 
children.  This finding emphasizes the role of a female as both a patient and a caretaker with regard 
to Fabry disease.  Healthcare providers should consider the dual role of patient and caretaker for 
their female patients when discussing Fabry disease treatment and disease monitoring.   
Participants also expressed concern for the progression of Fabry disease in themselves, 
including the development of more severe disease manifestations such as renal, cardiac, and 
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cerebrovascular complications. Recent data suggests that early initiation of treatment with ERT is 
critical to slow the progression of renal symptoms and that ERT provides clinical benefit with 
regard to cardiac manifestations, pain, and quality of life.37-42 In order to initiate treatment for a 
female with Fabry disease and provide clinical benefit for disease manifestations, she must first 
meet criteria established by Eng et al. (2006) based on degree of symptomology.  Degree of 
symptomology is characterized by the measurement of biomarkers and clinical assessments that 
are recommended to be performed annually based on published guidelines for the care of females 
with Fabry disease.4  For patients concerned with disease progression, a discussion of the 
importance of regular evaluations to determine eligibility for ERT, which has the potential to slow 
the progression of or stabilize renal and cardiac manifestations, may help with compliance for 
recommended evaluations, as well as provide support for females worried about disease 
progression. Healthcare providers can utilize this discussion both to reduce worry for their female 
patients and simultaneously emphasize the importance of clinical evaluations from a perspective 
unique to females with Fabry disease. 
4.4 SPECIFIC AIM THREE 
4.4.1 Characterization of perceived susceptibility to Fabry disease manifestations 
Perceived susceptibility to Fabry disease symptoms for males and females was calculated from a 
series of questions in which participants were asked to identify symptoms that males could have 
and that females could have (Table 13).  All of the symptoms participants could select from are 
symptoms associated with Fabry disease (Table 11).  The percentages of symptoms marked for 
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males compared to symptoms marked for females were equivalent, suggesting that participant’s 
believed that males with Fabry disease and females with Fabry disease are both at risk to develop 
the same symptoms.  Combined interpretation of the analyses for perceived severity and perceived 
susceptibility illustrates that participants believed that Fabry disease varied in severity for females 
compared to males, but that both males and females are equally susceptible to Fabry disease 
symptoms.  This understanding of Fabry disease is consistent with the current understanding of 
the medical community.6 Certain symptoms, including pulmonary disease and congestive heart 
failure, were marked with less frequency than other symptoms for both males and females.  As 
participants were consistent in marking these symptoms with less frequency for both sexes, it is 
possible that participants were less aware that these symptoms are associated with Fabry disease.  
Increased education about pulmonary disease and congestive heart failure as Fabry disease 
manifestations may be needed to address this decreased awareness. 
Analysis regarding Fabry disease susceptibility for males and females suggests that 
participants have an appropriate understanding of Fabry disease risks for females in general.  
However, comparison of perceived susceptibility of females to perceived personal susceptibility 
of participants suggests that participants do not apply that same accurate understanding to their 
own personal risks for the development of Fabry disease symptoms. Analysis showed that 
participants were more likely to indicate a Fabry disease symptom could develop for females than 
for themselves personally (Table 14 and Figure 11). Analysis from Part 1 of the three-part project 
also demonstrated this same phenomenon in which participants indicated an appropriate 
understanding of the risks for females to develop Fabry disease manifestations, but demonstrated 
a decreased perceived personal susceptibility to Fabry disease manifestations.  In 1999 Lippman 
described a similar experience in a population of females at increased risk to have a pregnancy 
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with Down syndrome due to advanced maternal age.  Females demonstrated an appropriate 
comprehension of the risks associated with advanced maternal age, but did not apply that same 
understanding to their own perception of risk.  Lippman (1999) described that these females 
negotiated with biomedical information by incorporating their own instincts, beliefs and personal 
experiences into their conception of risk, resulting in a decreased personal perceived 
susceptibility.63 It is possible that females with Fabry disease similarly incorporate psychosocial 
and structural modifying variables, such as worry, guilt, or experience with Fabry disease, into 
their perception of personal susceptibility to Fabry disease manifestations. 
It is possible that the difference in perceived personal susceptibility and perceived 
susceptibility of females demonstrated in this study is the result of the utilization of defense 
mechanisms, such as denial, by participants in an attempt to cope with their diagnoses.  Defense 
mechanisms are unconscious responses to a real or perceived threat that attempt to maintain some 
measure of control and reduce painful or uncomfortable emotions.64 Denial of personal risk for 
Fabry disease symptoms, which was self-identified by a participant as a barrier to evaluation and 
treatment (Table 19), may be an explanation for this difference in perception of disease 
susceptibility.  Denial of symptoms would include rejecting the possibility that an individual has 
or could develop symptoms.  Furthermore, approximately 16% of participants indicated that their 
symptoms were not severe and that this lack of severity acted as a barrier for the completion of 
recommended assessments (Table 18).  It is possible that females with these barriers would not 
comply with recommended evaluations and treatment, as they would not perceive personal benefit 
from these assessments.  
Results from this current study provide evidence that females with Fabry disease are 
appropriately educated about the risks to develop Fabry disease manifestations, but that this 
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education is not incorporated into their perception of personal susceptibility to Fabry disease 
manifestations.  These results suggest that investigation of perceived personal susceptibility by 
healthcare providers is warranted even if a female patient communicates an appropriate 
understanding of risk for females with Fabry disease.  Lippman  (1999) suggests that practices of 
genetic counselors including active listening and discussion rather than education are critical to 
address the incorporation of modifying variables such as instincts, beliefs, and personal 
experiences in the perception of susceptibility.63 In addition to educating female patients about 
risks for symptom development, health care providers should employ active listening and engage 
female Fabry disease patients in conversation to identify possible modifying variables, including 
personal beliefs, burden, experiences, and coping mechanisms such as  denial, that may be 
impacting perceived personal susceptibility. Healthcare providers may then be able to address 
these modifying variables and potentially recognize the decreased perceived personal 
susceptibility demonstrated in this analysis.   
Differences of statistical significance between susceptibility of females in general and 
participants personally were observed for the symptoms of proteinuria, congestive heart failure, 
enlargement of heart, stroke, chronic pain, abdominal pain, angiokeratomas, kidney failure, heart 
attack, transient ischemic attack, problems with sweating, corneal whorls, and depression and 
anxiety.  The four symptoms of pulmonary disease (p-value of 0.0098), heat/cold intolerance (p-
value of 0.0269), abnormal heart rhythm (p-value of 0.0162), and burning/numbness/tingling (p-
value of 0.0133) demonstrated the trend described above in which participants were more likely 
to indicate a Fabry disease symptom could develop for females than for themselves personally.  
Even though effects of nominal significance were observed for these symptoms, none of the results 
met the stricter threshold for statistical significance after adjustment of the number of tests were 
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considered. This was likely due to the small population size of this study.  Further investigation 
may help to determine if participants feel more personal susceptibility to these symptoms than to 
the other Fabry disease symptoms. 
4.4.2 Assessment of the term “carrier” 
Analyses were completed to determine the usage and perceived appropriateness of the term 
“carrier” (Figure 10).  Approximately 60% of participants had used the term “carrier” to describe 
themselves at some point in time compared to 40% of participants who currently believed the term 
was an inappropriate description of themselves.  This difference in personal usage and perceived 
appropriateness of the term “carrier” in combination with written justifications provided by 
participants suggests that some of these participants may have used the term “carrier” to describe 
themselves in the past and not currently.  Additionally, approximately 77% of participants 
indicated that a physician or healthcare provider at some point in time had used the term  “carrier” 
to describe them.  The term “carrier” was still considered an appropriate term for heterozygous 
females by the medical community as recently as 2001.5  As there was no assessment of time or 
date with regard to usage of the term “carrier” by providers or participants, it is difficult to 
determine if healthcare providers had inappropriately labeled participants as a “carrier” based on 
the data collected.  Further investigation into how recently participants had been referred to or 
referred to themselves as “carriers” is needed in order to appropriately assess current usage of the 
term “carrier”. 
The majority of participants, approximately 60%, indicated that they believed the term 
“carrier” was an inappropriate description of their disease status.  Qualitative thematic analysis 
was utilized to examine responses between participants who perceived the term “carrier” as 
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appropriate and among those who perceived it as inappropriate (Table 15).  The analysis suggests 
a difference in the understanding of the meaning of the term “carrier” among participants who did 
and did not self-identify as “carriers”.  Participants who believed the term was inappropriate had 
a similar understanding of the meaning of the term “carrier” as the medical community, in that the 
term “carrier” denotes a lack of symptoms.5; 34 In contrast, participants who believed the term was 
appropriate did not share this understanding and believed that the term “carrier” meant the ability 
to pass on the disease independent of the ability to develop symptoms.  This analysis suggests that 
a female who self-identifies as a “carrier”, or perceives the term “carrier” as an appropriate 
description of herself, does not necessarily believe she is not at risk for or does not currently have 
Fabry disease symptoms.  Patient perceived appropriateness of the term “carrier” may not be a 
good indicator of perceived personal susceptibility as some patients may not believe this term 
reflects their ability to develop or have Fabry disease symptoms. Healthcare providers should 
either clarify their meaning of the word “carrier” to female patients or ask females to clarify their 
understanding of the word “carrier” to prevent possible miscommunication. For newly diagnosed 
female patients, healthcare providers could also initiate a discussion about the history of the term 
“carrier” within the Fabry disease community and the potential to encounter this term as a 
description for females with a GLA mutation on the Internet or in the literature. This discussion 
may help to provide context regarding the usage of the term “carrier” to describe females with 
Fabry disease and prevent potential miscommunications between healthcare providers and their 
patients.  
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4.5 SPECIFIC AIM FOUR 
4.5.1 Characterization of perceived benefits of treatment, evaluations and monitoring 
More than half of participants, approximately 57%, were currently receiving ERT (Figure 13).  
These participants were asked to describe their expectations of ERT in response to an open-ended 
question (Table 16).  Expectations described by participants were compared to known outcomes 
of ERT reported in the literature.  Expectations described by participants that are consistent with 
current literature regarding the clinical benefits of ERT are considered realistic or appropriate 
expectations, while expectations that are incongruent with the literature are considered unrealistic 
or inappropriate.  Expectations listed by patients such as to feel better and to have more energy are 
issues related to quality of life, which can be improved with ERT.40; 41 Additionally, expectations 
that ERT would stabilize organ damage, specifically kidney and heart, are also consistent with the 
current understanding of the effectiveness of ERT, although stabilization of renal and/or cardiac 
damage is not achieved in every individual who receives ERT and may depend on when ERT is 
initiated in the disease course.37-39; 42  The interpretation of the appropriateness of the expectation 
“improve symptoms” depended to a degree on the specificity of the individual responses of the 
participants who described this expectation.  For example, the expectation that ERT would 
improve all symptoms is not supported by current data.  However, the expectations that ERT would 
improve pain and proteinuria are consistent with current evidence.37-41  Expectations listed by 
participants including prevention of symptoms, specifically stroke and renal, and prolongation of 
life are controversial in nature and have yet to be proven as benefits of ERT.7; 12 The expectation 
that ERT would cause an individual to lose weight could not be corroborated by literature review.   
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Not all of the expectations described by participants were consistent with known clinical 
benefits associated with initiation of ERT, suggesting that further education about the benefits of 
limitations of ERT to female patients may be needed.  Discussions of the specific benefits and 
limitations of ERT, as well as the tests used to measure effectiveness of ERT should take place 
between healthcare providers and females who meet criteria to receive ERT.  Furthermore, 
healthcare providers should investigate what specific symptoms females might expect to improve 
in order to better assess if the expectation of “improve symptoms” is realistic for their individual 
patients.  By assisting their patients to set appropriate expectations, healthcare providers may 
improve the perceived benefit to treatment with ERT by preventing the formation of unattainable 
expectations. 
Qualitative thematic analysis was utilized to determine if participants currently receiving 
ERT had a positive or negative experience based on the nature of the language used by participants 
in description of their ERT experience (Figure 12).  A significant amount of participants, 
approximately 37%, used negative language to describe their experience with ERT.  These 
participants communicated frustration with ERT and indicated feeling worse after initiation of 
ERT.  In addition, 14% of participants seemed to be grappling with their experience.  These 
participants either were unsure about how to feel about their experience being treated with ERT or 
used a combination of both positive and negative language when describing ERT.  Therefore, 
approximately 51% of participants did not seem to have a positive experience with ERT and may 
not perceive benefits to treatment based on this analysis. Efforts can be made by healthcare 
providers to explore their female patients’ satisfaction with ERT and to attempt to address issues 
or misconceptions that could lead to decreased perceived benefit. 
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4.6 SPECIFIC AIM FIVE 
4.6.1 Characterization of perceived barriers to treatment, evaluations and monitoring 
Participants were asked to indicate what barriers prevented them from completing recommended 
evaluations and monitoring.  The aim was to identify the most common barriers to females with 
Fabry disease in order to develop strategies and interventions to reduce possible barriers.  
Interestingly, a significant proportion of participants, approximately 36%, indicated that they had 
no barriers to treatment and evaluation (Figure 13).  This proportion is larger than was expected 
based on the clinical experience of investigators.  Of the 64% of participants who indicated at least 
one or more barrier to evaluations, the most common barrier, indicated by approximately 36% of 
participants, were costs not covered by insurance (Table 18).  These costs were identified by 
participants as prescriptions unrelated to ERT, copays, high deductibles, and costs of examinations 
and evaluations (Table 20).  Cost was not only identified as a barrier for participants, but also as a 
significant source of worry (Table 8).  Issues related to financial concerns were previously 
identified as a barrier to ERT43; however, analyses in this study suggest that the burden of cost 
may be underappreciated by healthcare providers.  As females with Fabry disease play both the 
role of patient and caretaker, costs are incurred from personal healthcare as well as from healthcare 
of relatives.  Healthcare providers can make efforts to make patients and families aware of financial 
assistance resources to help decrease this barrier.  Organizations such as Patient Services, Inc. 
(https://www.patientservicesinc.org/) that provide financial assistance for insurance deductibles, 
co-payments, and incidental medical expenses should be offered by healthcare providers as 
resources for patients with issues regarding costs not covered by insurance. 
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Other barriers indicated with increased frequency by participants included distance from 
centers (approximately 30%), anxiety (approximately 25%), and feeling overwhelmed 
(approximately 20%).  Distance from centers may be a difficult barrier for healthcare providers to 
address for all patients, as it is relative to the patient and the clinic resources.  This analysis does 
suggest that the facilitation of homecare, when possible, for those females receiving ERT may be 
important to decrease the barriers of distance.  For all patients regardless of treatment status, 
assistance with costs associated with distance and travel including gas and parking may be an 
alternative means to address this barrier.  Anxiety can be both a disease feature of Fabry disease 
and a secondary complication from increased worry.29 Treatment with medication or evaluation 
by a psychiatrist or psychological counseling may help females with chronic anxiety and it is 
important for the Fabry healthcare professionals to assess this possibility and provide patients with 
referral information when appropriate. In addition, healthcare providers may be able to reduce the 
barriers of anxiety and feelings of being overwhelmed by using the aforementioned strategies 
discussed above to reduce worry prior identified in this analysis and discussing reasonable 
expectations and goal setting.   
Guilt was identified with less frequency in this analysis; however, it was identified 
throughout the responses of open-ended questions pertaining to worry and feelings after diagnosis.  
Guilt was also identified in the Part 1 study as a significant barrier to evaluation and treatment.  
Guilt may be difficult for participants’ to self-identify in this format and may be better assessed 
and addressed in the form of personal interview.  Although guilt was not identified as a common 
barrier within this analysis, the identification of guilt in the Part 1 study as well as within the open-
ended responses in this project delineate the important role that guilt may play in the formation of 
the perceived health beliefs of females with Fabry disease.  Feelings of guilt have been associated 
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with a diagnosis of Fabry disease and may impact the willingness of females to complete 
recommended evaluations.24 As personal interviews may be a more effective format to address 
guilt than a written survey, healthcare providers may want to engage their female patients in a 
discussion about guilt to assess if it may be acting as a barrier to treatment and/or evaluation. 
4.7 SPECIFIC AIM SIX 
4.7.1 Modifying variables and cues to action: completion of recommended evaluations  
In order to assess compliance for females with Fabry disease, participants were asked to indicate 
what evaluations were recommended to them by healthcare providers and which of those 
evaluations they had completed both at the time of diagnosis and on a regular basis.  All of the 
evaluations listed for participants in the questionnaires were consistent with current guidelines for 
the management of females with Fabry disease described by Eng et al. (2006), except for the 
evaluation “kidney biopsy”.4  Kidney biopsies may be useful as a baseline assessment and in 
atypical presentations.  Repeat kidney biopsy is useful when disease is progressing despite 
therapy.65  For this reason, baseline kidney biopsies are often recommended by medical providers 
when initiating females on ERT. Interestingly, none of the evaluations recommended to 
participants were observed with a 100% frequency, suggesting that none of the evaluations were 
recommended to all of the participants (Table 22). This observation was unexpected as all of the 
evaluations should be recommended to all females with Fabry disease in accordance with 
recommended guidelines.4  Issues with recall bias, however, may be obscuring the true percentages 
of evaluations recommended to participants.  Assessment of the physicians and healthcare 
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providers managing Fabry disease for these participants may provide some clarification as to 
whether or not the lower percentages of recommended evaluations were due to physician error, 
recall bias, or to personal medical circumstances of patients.  Clarification as to the explanation 
for the reduced frequencies of recommended evaluations may help to determine if further 
education of healthcare providers regarding the recommended guidelines for the management of 
females with Fabry disease is indicated. 
In general, recommended evaluations were more often completed after diagnosis than on a 
continuous basis (Figure 14).  The reason for this trend may be due to increased motivation from 
feelings at diagnosis including fear or concern for self.  It is also possible that participants 
perceived increased benefits and/or decreased barriers to evaluations and monitoring at the time 
of diagnosis compared to later in management.  Assessment of females soon after diagnosis may 
bring clarification to these possible explanations.  Certain evaluations including 
electrocardiogram, echocardiogram, and lipid panel were completed more often on a continuous 
basis than at diagnosis.  It is possible that the evaluations excluding the lipid panel, 
electrocardiogram, and echocardiogram were perceived as too cumbersome or time consuming to 
complete on a regular basis.  Perhaps participants did not remember the completion of a lipid panel 
at the time of diagnosis, as it is a less invasive test compared to the other evaluations.  
Alternatively, it is possible that physicians order a lipid panel more often at subsequent visits than 
at the time of diagnosis. Electrocardiograms and echocardiograms are both evaluations that assess 
cardiac manifestations.  These evaluations were both recommended with frequencies of 95% and 
93% respectively.  These observations suggest that healthcare providers and participants may be 
particularly concerned with the development of cardiac manifestations. 
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Analyses failed to identify a statistically significant difference between evaluations 
recommended to and completed by participants. Some statistical evidence of decreased completion 
of recommended evaluations was noted for the evaluations of 24-hour holter monitor (p-value of 
0.0079), brain MRI (p-value of 0.0067), Fabrazyme antibody (p-value of 0.0228), and heart MRI 
(p-value of 0.0352) (See Table 22).  Even though effects of nominal significance were observed 
for these evaluations, none of these results met the more conservative threshold for Bonferroni 
adjustment.  The evaluations of 24-hour holter monitor, brain MRI, and heart MRI are typically 
considered time consuming and cumbersome examinations by patients. The burden associated 
with these evaluations may act as a barrier to participants and provide an explanation for the trend 
described above. Fabrazyme antibody, however, is a blood test used to evaluate the development 
of antibodies to treatment with ERT in individuals receiving ERT and is minimally invasive as 
compared to other evaluations.4 It is possible that participants did not recall that this test was 
performed during a clinical visit as it is less invasive, providing an explanation for the trend for 
this evaluation described in analysis.   
The potential effect of recall bias and its effect on the true percentages of evaluations 
recommended to participants may be complicating analysis of the completion of recommended 
assessments.  Further investigation into the completion of recommended evaluations should be 
pursued to confirm that females with Fabry disease truly do not have difficulties with compliance 
for recommended evaluations.    In addition, perceived severity for females with Fabry disease, 
amount of worry, and perceived personal susceptibility to Fabry disease manifestations were not 
associated with completion of recommended assessments. 
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4.7.2 Modifying variables: the impact of a diagnosis of Fabry disease 
All of the participants within the study reported a diagnosis of Fabry disease.  Thematic analysis 
was utilized to identify themes within the responses to the open-ended question regarding patients’ 
feelings after their diagnosis (Table 22). Participants expressed that at the time of diagnosis they 
experienced concern for children and other relatives in addition to personal concerns about 
prognosis.  These themes and the reported emotions of sadness, fear, guilt, and dread related to the 
diagnosis have been described within the literature regarding diagnoses of genetic conditions, 
providing further evidence that these emotions are associated with a diagnosis of Fabry disease.24 
Healthcare providers should continue to acknowledge these emotions as potential reactions to a 
diagnosis.  
Of note, not all feelings and emotions after diagnosis described by participants were 
negative.  A theme of validation was identified at the time of participants’ diagnoses.  These 
participants described relief in learning the cause of their personal symptoms or family history, as 
well as a sense of validation in confirming that their symptoms were not imagined.  Females with 
Fabry disease have an average 16.3-year delay in diagnosis from symptom onset due to diversity 
and non-specificity of symptoms and are more likely than males to be labeled as problem patients 
leading to dismissal by healthcare providers.6; 9; 35 This analysis suggests that the participants may 
have experienced these same issues described in the literature and that diagnosis provided a 
resolution to resulting frustrations.  Healthcare providers should therefore not presume that all 
feelings resulting from diagnosis will be negative.  The three themes of concern for children and 
other relatives, concern for self, and validation were often expressed simultaneously in 
participants’ responses, signifying the complexity of emotions felt at the diagnosis.  Knowledge 
of these issues may help health care providers to be better prepared to address these concerns at 
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the time of diagnosis or in subsequent visits, helping providers to build rapport and improve 
communication with their female patients. 
In addition to the themes discussed above, a theme of indifference was identified for 
participants diagnosed in childhood, for those labeled incorrectly as asymptomatic carriers at the 
time of diagnosis, and for those participants who anticipated that they would be diagnosed with 
Fabry disease.  With the increase of newborn screening initiatives in the United States, diagnoses 
of Fabry disease may be occurring at younger ages in the future.  It is possible that feelings of 
indifference or delayed reaction toward a diagnosis of Fabry disease may increase in the future 
due to increased diagnoses at younger ages.  However, as literature continues to provide evidence 
of heterozygous females with significant Fabry disease manifestations, participants may be less 
likely to feel indifferent about a diagnosis of Fabry disease due to incorrect labeling as a carrier.  
The education of healthcare providers, however, is critical in the reduction of females being 
mislabeled as carriers not at risk for disease manifestations.   
The majority of participants, approximately 75%, reported that their diagnoses of Fabry 
disease impacted their ideas about their health (Figure 15).  Thematic analysis was performed on 
responses to the open-ended question to determine the ways in which health beliefs were impacted 
(Table 22).  The theme of hyperawareness of health issues seemed to burden participants who 
described this experience.  Healthcare providers may be able to lessen this burden by helping 
patients to identify what symptoms may be related or unrelated to Fabry disease as symptoms are 
often diverse and nonspecific.6   
Changes in healthcare practices were also identified as a theme for participants whose 
health beliefs were impacted.  These changes mostly included alterations in diet and increased 
exercise.  While certain diets and exercise practices are associated with decreased risk for chronic 
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health conditions including cardiovascular disease and diabetes mellitus type 2 and are generally 
recommended by organizations including the World Health Organization (WHO), the United 
States Department of Agriculture (USDA), and the United States Department of Health and 
Human Services (HHS), their benefits have yet to be recognized for the prevention or treatment of 
chronic genetic conditions such as Fabry disease.  Healthcare providers may want to provide 
clarification about the health concerns targeted by these interventions and explain to patients that 
these changes may help to prevent the development of compounding chronic health conditions, 
but will not specifically prevent or treat Fabry disease complications in order to reduce or prevent 
frustrations resulting from ineffective health practices.   
A theme of change in perception of health was identified for participants.  Changes in 
perception of health expressed by participants including shortened lifespan and reduced quality of 
life are consistent with current literature that states that females with Fabry disease have poor self-
perception of health and reduced quality of life.5; 48 In addition to these negatively associated 
changes in perception of health, this study also identified a positive impact on perception of health.  
Similar to the theme of validation identified in feelings at the time of and after diagnosis, 
participants expressed relief in understanding the cause of their health concerns and an 
appreciation of being able to better comprehend their health issues and the health issues of family 
members.  Educating patients about Fabry disease may help participants to correct 
misunderstandings of disease that could lead to poor self-perception of health or to replace a poorer 
self-perception of health with an improved understanding of health. 
Another theme with regard to impact on health beliefs was increased worry regarding 
insurance and work discrimination, long-term issues resulting from Fabry disease, and inevitable 
deterioration of health.  These concerns relate to topics of worry identified in the thematic analysis 
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of topics of worry about Fabry disease described in Specific Aim Two.  Long-term issues and 
deterioration of health relate to the prior identified theme of disease progression as a source of 
worry. Additionally, insurance and work discrimination concerns relate to uncertainty related to 
the availability of treatment and management options, which was largely associated with insurance 
coverage. These concerns are focused on potential financial barriers to treatment, evaluations and 
monitoring. This analysis provides further evidence that females with Fabry disease are 
significantly impacted by worry, particularly regarding the inevitability of disease progression and 
financial concerns associated with treatment and management.   
 Analysis from this study suggests that reactions to diagnosis are complex in nature and 
include emotions ranging from sadness to relief and validation.  Female patients may feel a 
combination of concerns for both their own health and the health of their relatives.  Reviewing the 
impact of the diagnosis on the personal management for female patients, as well as the potential 
impact for their relatives may be important to comprehensively address patient concerns.  In 
addition, female patients may feel a sense of validation from their diagnosis and healthcare 
providers can acknowledge and encourage this reaction to increase potential positive reactions to 
diagnosis.  Healthcare providers should also be aware patients diagnosed at younger ages may 
adjust to diagnoses differently than individuals diagnosed in adulthood.  Diagnoses of Fabry 
disease have the potential to impact female patients’ ideas about their health.  Education about 
symptoms associated with Fabry disease and the appropriate management and treatment of these 
symptoms may reduce misconceptions that lead to poor self-perception of health and frustration 
from the utilization of ineffective healthcare practices. The impact of worry, specifically regarding 
disease progression and financial concerns associated with treatment and management, may serve 
as a significant burden to females with Fabry disease.  Healthcare providers should utilize 
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strategies discussed within “perceived severity” (Specific Aim Two) to address these concerns 
including the discussion of treatment with ERT for females and their relatives and the discussion 
of resources for financial assistance. 
4.7.2.1 Modifying variables: participants currently receiving ERT compared to participants 
not currently receiving ERT 
Analyses of perceived severity, perceived susceptibility, perceived barriers to evaluations and 
monitoring, and completion of recommended evaluations were performed to characterize potential 
differences between participants currently receiving and not receiving ERT.  A trend was identified 
in which participants receiving ERT felt more personally susceptible to the symptoms of chronic 
pain (p-value of 0.006), heat/cold intolerance (p-value of 0.002), abdominal pain (p-value of 0.03), 
burning/numbness/tingling (p-value of 0.01), and diarrhea/constipation (p-value of 0.03) (Table 
24 and Figure 15).  Perceived personal susceptibility is defined in this analysis as to have or feel 
likely to develop a symptom. The symptoms listed above are not considered life-threatening 
manifestations of Fabry disease, but are all associated with poor quality of life.48  This trend 
suggests that perceived susceptibility for symptoms associated with quality of life may be higher 
in females receiving ERT than those not receiving ERT. Females receiving ERT must meet criteria 
established by Eng et al. (2006) based on measurements and evaluations largely related to life-
threatening cardiac, renal, and cerebrovascular manifestations. The presence of chronic 
acroparasthesias resistant to conventional therapy or of chronic or disabling gastrointestinal 
distress are the only criteria for ERT initiation related to quality of life.4  Thus, participants 
receiving ERT most likely had symptoms of renal, cardiac, or cerebrovascular manifestations of 
Fabry disease, as well as the aforementioned symptoms related to quality of life. Of note, early 
signs of renal or cardiac disease such as proteinuria or mild left ventricular hypertrophy, in contrast 
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to the symptoms associated with quality of life, may not produce symptoms experienced by a 
patient.  This evidence brings into question whether symptoms associated with quality of life, or 
even more simply that symptoms that are noticeable to patients, are stronger motivators for 
treatment with ERT than life-threatening symptoms that might qualify a female for treatment.  
Healthcare providers may want to emphasize the ability of ERT to treat symptoms associated with 
quality of life in discussions regarding the potential initiation of ERT for their female patients as 
these symptoms may act as internal cues to action for the initiation of ERT.40; 41 While this trend 
is very compelling for the symptoms of chronic pain, abdominal pain, burning/numbness/tingling, 
and diarrhea/constipation, the associated p-values do not meet the stricter threshold for statistical 
significance.   
Participants currently receiving ERT indicated the barrier of “symptoms are not severe” 
with less frequency than participants not receiving ERT (p-value of 0.03) (Table 25 and Figure 
16).  This observation is logical, as females receiving ERT must have symptoms considered 
significant enough to warrant initiation of ERT.4  While this observation does show some degree 
of nominal significance, it does not meet the more conservative threshold for statistical 
significance after adjustment for the number of tests considered. 
4.7.2.2 .Modifying variables: participants who indicated no barriers to evaluations and 
monitoring compared to participants with one or more barrier 
Analyses of perceived severity, perceived susceptibility, current treatment with ERT, and 
completion of recommended assessments were performed to characterize potential differences 
between participants with and without barriers to evaluations and monitoring.  A trend was 
observed in which participants who indicated no barriers to evaluations and monitoring had a 
higher income than those participants who indicated one or more barrier to evaluations and 
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monitoring (p-value of 0.012).  This observation is of particular interest as the most frequent barrier 
indicated by participants was related to cost, providing further evidence that cost is a significant 
burden for females with Fabry disease and that efforts should be made by healthcare providers to 
provide resources for financial assistance to their female patients with Fabry disease.  While this 
trend seems compelling, it fails to meet the conservative threshold for Bonferroni adjustment.   
4.8 LIMITATIONS 
This study was not without limitations.  The small population size of the study limits the power of 
the analysis.  Both the study design in which investigators could not directly contact potential 
participants and the rarity of the condition constrained the ability of investigators to acquire a 
larger study population.  Certain limitations are inherent in the study design. Self-reporting of 
personal medical information is subject to recall bias.  The open-ended format of certain questions, 
while critical to the characterization of the health beliefs of females, occasionally resulted in 
participants describing an experience unrelated to the question.  This led to the exclusion of certain 
responses from qualitative thematic analysis.  In addition, investigators re-contacted three 
participants for clarification about responses for the questions assessing perceived susceptibility 
and perceived severity for males.  These participants did not believe they were supposed to answer 
those questions at the time they completed the questionnaire.  There was an inability to confirm 
reported diagnoses of Fabry disease. However, it is unlikely that participants incorrectly labeled 
themselves as diagnosed with Fabry disease as a diagnosis of Fabry disease was defined for 
participants.   
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Approximately 14% of participants could not be localized into a region of the United States 
based on management location due to issues such as lack of current management or non-localizable 
management, an example being the Lysosomal Storage Disease Clinical Care Network which has 
numerous clinics located within multiple regions of the United States.  This inability demonstrates 
a limitation of this methodology.  In addition, this analysis suggested that this study succeeded in 
recruiting participants  with a relatively even distribution from four regions of the United States 
(Northeast, South, Midwest, and West); however, not all divisions, defined by the US Census 
Bureau as small groupings of states within a region, are equally represented.  This is a limitation 
of the small population size of the study.  Finally, there was a limitation inherent in the analysis of 
perceived susceptibility to Fabry disease manifestations.  In the questionnaire participants were 
asked to indicate what symptoms could develop, or were “possible”, in females with Fabry disease.  
In contrast, participants were then asked to indicate what symptoms were “likely” to develop for 
them selves.   It is possible that participants perceived these two questions differently and that the 
difference in perceived personal susceptibility as compared to perceived susceptibility of females 
described in this analysis was partially due to the different wording of the two questions.  It is 
unlikely, however, that this would entirely explain the statistically significant differences between 
the perceived susceptibility of females and perceived personal susceptibility as the p-value for 
statistical significance was adjusted to a more conservative value.  In addition, this phenomenon 
was also identified in Part one analysis of the three-part study and has also been reported among 
another population of at-risk females within the literature,63 providing further evidence that the 
difference wording may not be the explanation for the differences in perceived susceptibility. 
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5.0  CONCLUSIONS 
This study was unable to recruit the first specific aim of 50 study participants, however, this 
inability was likely due to limitations within the study design and regarding the study of a rare 
genetic disease.   
The second specific aim of this study was to characterize the perceived severity of females 
with Fabry disease.  Analysis from this study demonstrates that participants had an appropriate 
understanding of Fabry disease severity for both males and females, suggesting that current 
educational measures are successfully communicating the variability of Fabry disease for females 
as compared to males.  In addition, female patients may be significantly burdened by worry, 
highlighting the need for healthcare providers to investigate the specific worries that burden their 
female patients.  Healthcare providers should engage their female patients in conversation about 
potential sources of worry as the majority of sources of worry identified from this analysis may 
able to be addressed and/or reduced by healthcare providers using a variety of different strategies.  
Reduction  of worry for female patients may lead to improved rapport and communication, and 
the potential reduction of barriers to evaluations and treatment.   
The third specific aim of this study was to characterize the perceived susceptibility of 
females to Fabry disease manifestations.  Results from this study provide evidence that females 
with Fabry disease are appropriately educated about the risks to develop Fabry disease 
manifestations, but that they view their personal susceptibility in a different manner.  These results 
suggest investigation by healthcare providers is warranted to assess personal perceived 
susceptibility even if a female patient communicates an appropriate understanding of risk for 
females with Fabry disease. In addition to educating female patients about risks for symptom 
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development, health care providers should employ active listening and engage female Fabry 
disease patients in conversation to identify possible modifying variables, including personal 
beliefs, burden, experiences, and coping mechanisms such as denial, that may be impacting 
perceived personal susceptibility. Healthcare providers may then be able to address these 
modifying variables and potentially address the decreased perceived personal susceptibility 
demonstrated in this analysis. In addition, analysis regarding the perceived appropriateness of the 
term “carrier” suggests that a female who self-identifies as a “carrier”, or perceives the term 
“carrier” as an appropriate description of herself, does not necessarily believe she is not at risk for 
or does not currently have Fabry disease symptoms.  Patient perceived appropriateness of the term 
“carrier” may not be a good indicator of perceived personal susceptibility as some patients may 
not believe this term reflects their ability to develop or have Fabry disease symptoms. Healthcare 
providers should either clarify their meaning of the word “carrier” to female patients or ask females 
to clarify their understanding of the word “carrier” to prevent possible miscommunication.  
The fourth specific aim of this study was to characterize the perceived benefits to treatment 
with ERT.  Not all of the expectations of ERT described by participants were consistent with 
known clinical benefits associated with initiation of ERT, suggesting that further education about 
the benefits of limitations of ERT is needed for females with Fabry disease.  Discussions of the 
specific benefits and limitations of ERT, as well as the tests used to measure the effectiveness of 
ERT should take place between healthcare providers and females who meet criteria to receive 
ERT. By assisting their patients to set appropriate expectations, healthcare providers may improve 
the perceived benefit to treatment with ERT by preventing the formation of unattainable 
expectations.  In addition, a number of participants demonstrated a negative experience with ERT 
or seemed to be grappling with how to feel about their experiences being treated with ERT.  This 
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analysis suggests that some female patients may not perceive benefits to treatment due to issues 
with frustration, feeling worse, or uncertainty of expectations. Efforts can be made by healthcare 
providers to explore their female patients’ satisfaction with ERT and to attempt to address issues 
or misconceptions that could lead to decreased perceived benefit. 
The fifth specific aim of this study was to characterize the perceived barriers to treatment 
and evaluations for females with Fabry disease.  Analyses from this study suggest that the burden 
of cost may be underappreciated by healthcare providers. Healthcare providers can make efforts 
to make patients and families aware of available financial assistance resources to help decrease 
this barrier.  In addition, distance from centers, anxiety, and feeling overwhelmed may also act as 
barriers for females with Fabry disease.  Healthcare providers can utilize a variety of approaches 
to reduce these barriers including providing financial assistance for travel and by facilitating 
homecare for females receiving ERT, as well as by employing strategies to reduce sources of worry 
such as education, advocacy, and referral to counseling services.. 
The sixth specific aim was to characterize differences among the study population that may 
affect health beliefs, including potential modifying variables and cues to action.  Analyses failed 
to identify a difference of statistical significance between evaluations recommended to and 
completed by participants.  Issues with recall bias, however, may be obscuring the true percentages 
of evaluations recommended to participants.  Assessment of the physicians and healthcare 
providers managing Fabry disease for these participants may provide some clarification as to 
whether or not the lower percentages of recommended evaluations were due to physician error, 
recall bias, or to personal medical circumstances of patients.  Clarification as to the explanation 
for the reduced frequencies of recommended evaluations may help to determine if further 
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education of healthcare providers regarding the recommended guidelines for the management of 
females with Fabry disease is indicated.  
Analysis from this study suggests that reactions to diagnosis are complex in nature and 
may impact the health beliefs of a patient.  Female patients may feel a combination of concerns 
for both their own health and the health of their relatives.  Reviewing the impact of the diagnosis 
on the personal management for female patients, as well as the potential impact for their relatives 
may be important to comprehensively address patient concerns.  In addition, female patients may 
feel a sense of validation from their diagnosis and healthcare providers can acknowledge and 
encourage this reaction to increase potential positive reactions to diagnosis.  Healthcare providers 
should also be aware patients diagnosed at younger ages may adjust to diagnoses differently than 
individuals diagnosed in adulthood. Education about symptoms associated with Fabry disease and 
the appropriate management and treatment of these symptoms may reduce misconceptions that 
lead to poor self-perception of health and frustration from the utilization of ineffective healthcare 
practices.  
Analyses were performed to characterize potential differences among females currently 
receiving ERT and not currently receiving ERT as treatment with ERT was theorized as a possible 
modifying variable for females with Fabry disease.  Analysis identified that participants currently 
receiving ERT typically had greater perceived susceptibility to symptoms associated with quality 
of life than participants not currently receiving ERT.  This evidence brings into question whether 
symptoms associated with quality of life, or even more simply that symptoms that are noticeable 
to patients, are stronger motivators for treatment with ERT than life-threatening symptoms that 
might qualify a female for treatment.  Healthcare providers may want to emphasize the ability of 
ERT to treat symptoms associated with quality of life in discussions regarding the potential 
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initiation of ERT for their female patients as these symptoms may act as internal cues to action for 
the initiation of ERT. 
Finally, analyses were performed to identify potential modifying variables for participants 
who indicated no barriers to evaluations and monitoring as compared to participants who indicated 
one or more barrier to evaluations and monitoring.  A trend was observed in which participants 
who indicated no barriers to evaluations and monitoring had a higher income than those 
participants who indicated one or more barrier to evaluations and monitoring, providing further 
evidence that cost is a significant burden for females with Fabry disease and that efforts should be 
made by healthcare providers to provide resources for financial assistance to their female patients 
with Fabry disease.   
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6.0  FUTURE RESEARCH OPPORTUNITIES 
This study is a part of a larger three-part project aimed at assessing both the health beliefs of 
females diagnosed and at-risk for Fabry disease and the beliefs of medical providers about the 
importance of clinical evaluation, continued monitoring, and treatment for these females.  The 
future study (Part 3) will aim to characterize the beliefs of medical providers about the 
importance of clinical evaluation, continued monitoring, and treatment for diagnosed or at-risk 
females, as well as to assess provider adherence to published recommendations for the 
management of females.  A modified questionnaire will be created to assess healthcare 
providers listed by participants in this current study (Part 2) to maintain continuity of this 
project.  Future assessment of the beliefs of healthcare providers will provide clarification 
regarding potential recall bias regarding evaluations recommended to participants from this 
current study, as well as allow for further investigation of the current usage and perceived 
appropriateness of the term “carrier” by healthcare providers.  Combined analysis from all 
three parts of this project will provide a comprehensive investigation into the health beliefs of 
both adult females with Fabry disease and the healthcare providers who manage them, leading 
to the identification of sources of miscommunication and potential barriers for both females 
patients and healthcare providers that may lead to poor patient outcomes.  Increased awareness 
of patient and provider miscommunication and barriers, as well as strategies developed to 
address burdens, common sources of misunderstandings, and barriers have the potential to 
improve communication between patients and their healthcare providers and ultimately lead to 
improved patient outcomes. 
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In addition to the completion of Part 3 of this project, data from this analysis could be 
used to create a revised questionnaire utilized in the clinical setting by healthcare providers, 
such as genetic counselors or physicians, as a means to initiate a dialogue about potential 
worries, perceived susceptibility, and perceived benefits and barriers to treatment, evaluation 
and monitoring. Future studies could be pursued to assess the effectiveness of the revised 
questionnaire in addressing issues for females diagnosed with Fabry disease and the reduction 
of perceived barriers by using a survey to determine perceived improvement in patient-
provider interactions, compliance to recommended evaluations and treatment, and perceived 
reduction of barriers to treatment and evaluation. To better assess perceived susceptibility, the 
revised questionnaire will investigate both what symptoms are “possible to develop” and what 
symptoms are “likely to develop” as separate questions for both females with Fabry disease 
and for the patients’ personally. Both patients and healthcare providers should be included in 
this analysis.  Additionally, the creation of a more general questionnaire using data from this 
analysis may be helpful in the assessment of the health beliefs of females with other X-linked 
conditions such as ornithine transcarbamylase (OTC) deficiency or hemophilia A or B, 
providing public health significance to the findings of this study.  Future research may 
demonstrate the utility of these assessments in increasing communication between healthcare 
providers and their female patients and improving patient outcomes.   
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APPENDIX B: PARTICIPANT RECRUITMENT FLYER 
 116 
 
 117 
APPENDIX C: TELEPHONE CONSENT SCRIPT 
You are being asked to participate in a research study because of your diagnosis of Fabry 
disease/your family history of Fabry disease and at-risk status. The purpose of this research study 
is to better understand the health beliefs of women diagnosed and at risk for Fabry disease. To 
accomplish this, we will be surveying women over age 18 with a diagnosis of Fabry disease or at-
risk for the disease based on family history. Participants will be patients with a lysosomal storage 
disorders program or physician specializing in the care of patients with Fabry disease or have a 
family member who is a patient of a lysosomal storage disorders program or Fabry specialist.  
Women are asked to complete a 5-10 minute written demographics survey including 
questions about your background (including your age, race, years of education, and family history) 
and a 15-20 minute written questionnaire about health beliefs. This questionnaire will explore your 
understanding of and beliefs about Fabry disease and how those factors relate to your health and 
medical care. When possible, participants are encouraged to complete this questionnaire in the 
presence of their lysosomal disease healthcare team and to discuss their responses with those 
professionals. The written demographics survey and questionnaire will not contain your name but 
will be numbered so your responses can be linked. Additionally, you will be asked to list the names 
and contact information for your primary Fabry disease healthcare team if you are currently 
involved in management or treatment for this disease. This information will provide us with the 
ability to survey your healthcare providers about their health beliefs with regards to the medical 
management of females with Fabry disease. The survey questions will not ask the healthcare 
professional for any specific patient information or medical history.  
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All responses to the survey and questionnaire are confidential and responses will be stored 
in a secure manner. Personal password-protected computers and a locked file cabinet will be 
utilized. However, a potential risk of breach of confidentiality remains. Possible exceptions to 
maintaining confidentiality of your research information include audit of research by the 
University of Pittsburgh Research Conduct and Compliance Office and subpoena of research data 
by the courts. Research records for this study will be stored indefinitely. There is a possibility of 
direct benefit to you as a result of participating in this research study including improved 
communication with your lysosomal healthcare team about your health beliefs. However, there is 
no guarantee that you will receive such a benefit. There is also a potential general benefit to 
increasing the knowledge about women diagnosed or at-risk for Fabry disease. Each participant 
will receive a $20 electronic debit card in appreciation for your participation.  
 
Your participation is voluntary and you may withdraw from this project at any time. Your 
decision to participate or not participate will not impact your current or future relationship with 
the Lysosmal Storage Disorders Program or its staff, the University of Pittsburgh Medical Center, 
or the University of Pittsburgh.  
 
You are encouraged to ask questions, voice concerns or complaints about any aspect of this 
research study during the course of this study, and future questions, concerns or complaints will 
be answered by a qualified individual or by the Principal Investigator, Katie Long, at 412-692-
3475. You may always request that your questions, concerns or complaints be addressed by PI or 
co-investigator Dr. David Finegold. You may contact the Human Subjects Protection Advocate of 
the IRB Office, University of Pittsburgh (1-866-212-2668) to discuss problems, concerns, and 
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questions; obtain information; offer input; or discuss situations in the event that the research team 
is unavailable. 
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W e t r u l y a ppr eci a t e your  cont r i but i on t o our  
r esea r ch  st ud y.  
S i ncer el y,  
T he L ysosoma l  S t or a ge D i sor d er s P r ogr a m 
S t a f f  a t  t he C h i l d r en ’ s  
H ospi t a l  of  P i t t sbur gh  
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APPENDIX E: DEMOGRAPHIC SURVEY 
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Number_______ 
1 
We thank you for participating in this survey. It is intended to gather demographic information for our 
study of the health beliefs of females diagnosed and at-risk for Fabry disease. Your answers will be linked 
by number to your open-ended questionnaire. Please do not write your name on the survey. If there is a 
question that you do not feel comfortable answering, you can skip it and continue on.  Please answer the 
following questions to the best of your ability.  The survey should take approximately 5-10 minutes.  
Please return the survey by mail in the envelope provided along with your completed open-ended 
questionnaire. We would like to thank you in advance for your willingness to participate in this study. 
 
1) What is your age? 
__ __ age in years 
 
2) Which one or more of the following would you say is your race?  (Circle all that apply) 
1 White 
2 Black or African American 
3 Asian 
4 Native Hawaiian or Other Pacific Islander 
5 American Indian, Alaska Native 
6 Other [specify] __________________________  
 
3) Are you Hispanic or Latino? 
1 Yes 
2 No 
3 Don’t know 
 
4) What was the total household income from all sources last year? 
1 Less than $10,000 
2 Between $10,000 and $20,000 
3 Between $20,001 and $35,000 
4 Between $35,001 and $50,000 
5 Between $50,001 and $75,000 
6 Greater than $75,000 
 
5) What is the highest grade or year of school you completed?   
1 Grades 8 or less (Elementary) 
2 Grades 9 through 11 (Some high school) 
3 Grade 12 or GED (High school graduate) 
4 College 1 year to 3 years (Some college or technical school) 
5 College 4 years or more (College graduate or post-graduate) 
6 Graduate level (Masters or PhD) 
 
6) Are you currently employed (includes part and full time)? 
1 Yes 
2 No 
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Number_______ 
2 
7) What is your marital status? 
1 Single 
2 Married 
3 Divorced 
4 Separated 
5 Widowed 
 
8) Do you have any kind of health care coverage, including health insurance, prepaid plans such 
as HMOs, or government plans such as Medicare/Medicaid? 
1 Yes 
2 No 
3 Don’t know / Not sure 
 
9) Was there a time in the past 12 months when you needed to see a doctor but could not because 
of the cost? 
1 Yes 
2 No 
3 Don’t know / Not sure 
 
10) Do you have a diagnosis of Fabry disease? 
1 Yes 
2 No 
3 Don’t know / Not sure 
 
10a) If you answered “No” or “Don’t know” to the previous question, are you at risk to 
have inherited Fabry disease based on your family history? 
1 Yes 
2 No 
3 Don’t know / Not sure 
 
11) Do you have a family history of Fabry disease in any relative? 
1 Yes 
2 No 
3 Don’t know / Not sure 
  
11a) If you answered “Yes” to the previous question, please select all of your relatives 
who have ever been diagnosed with Fabry disease. 
 
⁫ Mother  ⁫ Maternal Grandfather  ⁫ Paternal Grandfather 
⁫ Father  ⁫ Maternal Grandmother  ⁫ Paternal Grandmother 
⁫ Brother  ⁫ Maternal Aunt   ⁫ Paternal Aunt 
⁫ Sister  ⁫ Maternal Uncle   ⁫ Paternal Uncle 
⁫ Son   ⁫ Maternal Cousin   ⁫ Paternal Cousin 
⁫ Daughter  ⁫ Niece    ⁫ Nephew 
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Number_______ 
3 
11b) If you answered “Yes” to question 11, have any of your relatives received treatment 
for Fabry disease with enzyme replacement therapy? 
1 Yes 
2 No 
3 Don’t know / Not sure 
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APPENDIX F: CLINICAL QUESTIONNAIRE 
 
 
 
Number____	  
1	  
Assessing	  Health	  Beliefs	  of	  Women	  Diagnosed	  and	  At	  Risk	  for	  Fabry	  Disease	  
Thank	  you	  for	  agreeing	  to	  complete	  this	  questionnaire.	  	  Please	  complete	  each	  question	  as	  instructed.	  
Symptoms	  of	  Fabry	  Disease	  
1. Based	  on	  your	  understanding,	  what	  symptoms	  can	  Fabry	  disease	  cause?	  (Mark	  all	  that	  apply)
In	  males:	  
□ Proteinuria	  (excess	  protein	  in	  the	  urine) □ Kidney	  failure
□ Congestive	  heart	  failure	  (heart	  cannot	  pump
enough	  blood	  to	  meet	  the	  body’s	  needs)
□ Heart	  attack
□ Enlargement	  of	  heart □ Abnormal	  heart	  rhythm	  (irregular	  heart	  beat)
□ Stroke □ Transient	  ischemic	  attack	  (mini-­‐stroke)
□ Chronic	  pain □ Burning/numbness/tingling	  in	  hands	  or	  feet
□ Heat	  and/or	  cold	  intolerance □ Problems	  with	  sweating
□ Abdominal	  pain □ Diarrhea	  and/or	  constipation
□ Angiokeratomas	  (clustered	  red	  skin	  markings) □ Corneal	  whorls	  (pattern	  on	  transparent	  area	  of
eye	  only	  visible	  by	  slit	  lamp	  exam)
□ Pulmonary	  (lung)	  disease □ Depression	  and/or	  anxiety
In	  females:	  
□ Proteinuria	  (excess	  protein	  in	  the	  urine) □ Kidney	  failure
□ Congestive	  heart	  failure	  (heart	  cannot	  pump
enough	  blood	  to	  meet	  the	  body’s	  needs)
□ Heart	  attack
□ Enlargement	  of	  heart □ Abnormal	  heart	  rhythm	  (irregular	  heart	  beat)
□ Stroke □ Transient	  ischemic	  attack	  (mini-­‐stroke)
□ Chronic	  pain □ Burning/numbness/tingling	  in	  hands	  or	  feet
□ Heat	  and/or	  cold	  intolerance □ Problems	  with	  sweating
□ Abdominal	  pain □ Diarrhea	  and/or	  constipation
□ Angiokeratomas	  (clustered	  red	  skin	  markings) □ Corneal	  whorls	  (pattern	  on	  transparent	  area	  of
eye	  only	  visible	  by	  slit	  lamp	  exam)
□ Pulmonary	  (lung)	  disease □ Depression	  and/or	  anxiety
127
Number____	  
2	  
2. What	  symptoms	  of	  Fabry	  disease,	  if	  any,	  do	  you	  have?	  (Mark	  all	  that	  apply)
□ Proteinuria	  (excess	  protein	  in	  the	  urine) □ Kidney	  failure
□ Congestive	  heart	  failure	  (heart	  cannot	  pump
enough	  blood	  to	  meet	  the	  body’s	  needs)
□ Heart	  attack
□ Enlargement	  of	  heart □ Abnormal	  heart	  rhythm	  (irregular	  heart	  beat)
□ Stroke □ Transient	  ischemic	  attack	  (mini-­‐stroke)
□ Chronic	  pain □ Burning/numbness/tingling	  in	  hands	  or	  feet
□ Heat	  and/or	  cold	  intolerance □ Problems	  with	  sweating
□ Abdominal	  pain □ Diarrhea	  and/or	  constipation
□ Angiokeratomas	  (clustered	  red	  skin	  markings) □ Corneal	  whorls	  (pattern	  on	  transparent	  area	  of
eye	  only	  visible	  by	  slit	  lamp	  exam)
□ Pulmonary	  (lung)	  disease □ Depression	  and/or	  anxiety
3. What	  symptoms	  of	  Fabry	  disease,	  if	  any,	  do	  you	  feel	  you	  are	  likely	  to	  develop?	  (Mark	  all	  that
apply)
□ Proteinuria	  (excess	  protein	  in	  the	  urine) □ Kidney	  failure
□ Congestive	  heart	  failure	  (heart	  cannot	  pump
enough	  blood	  to	  meet	  the	  body’s	  needs)
□ Heart	  attack
□ Enlargement	  of	  heart □ Abnormal	  heart	  rhythm	  (irregular	  heart	  beat)
□ Stroke □ Transient	  ischemic	  attack	  (mini-­‐stroke)
□ Chronic	  pain □ Burning/numbness/tingling	  in	  hands	  or	  feet
□ Heat	  and/or	  cold	  intolerance □ Problems	  with	  sweating
□ Abdominal	  pain □ Diarrhea	  and/or	  constipation
□ Angiokeratomas	  (clustered	  red	  skin	  markings) □ Corneal	  whorls	  (pattern	  on	  transparent	  area	  of
eye	  only	  visible	  by	  slit	  lamp	  exam)
□ Pulmonary	  (lung)	  disease □ Depression	  and/or	  anxiety
Seriousness	  of	  Fabry	  Disease	  
4. How	  serious	  is	  Fabry	  disease?
a. For	  a	  male:	  (circle	  one)
i. Fabry	  disease	  is	  very	  serious.
ii. Fabry	  disease	  is	  somewhat	  serious.
iii. Fabry	  disease	  can	  be	  serious,	  but	  is	  not	  always	  serious.
iv. Fabry	  disease	  is	  not	  serious.
b. For	  a	  female:	  (circle	  one)
i. Fabry	  disease	  is	  very	  serious.
ii. Fabry	  disease	  is	  somewhat	  serious.
iii. Fabry	  disease	  can	  be	  serious,	  but	  is	  not	  always	  serious.
iv. Fabry	  disease	  is	  not	  serious.
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5. What	  statement	  would	  you	  most	  agree	  with?	  (circle	  one)
i. I	  am	  very	  worried	  about	  Fabry	  disease.
ii. I	  am	  somewhat	  worried	  about	  Fabry	  disease.
iii. I	  am	  worried	  very	  little	  about	  Fabry	  disease.
iv. I	  am	  not	  worried	  about	  Fabry	  disease.
a. If	  you	  are	  worried	  about	  Fabry	  disease,	  what	  worries	  you	  the	  most?	  	  Please
describe.
Inheritance	  of	  Fabry	  Disease	  
6. Based	  on	  your	  understanding,	  how	  is	  Fabry	  disease	  passed	  on	  in	  a	  family?
7. Have	  you	  ever	  used	  the	  word	  carrier	  to	  describe	  yourself?
□ Yes □ No
a. Have	  any	  of	  your	  physicians	  or	  health	  care	  providers	  used	  the	  word	  “carrier”	  to	  describe
your	  diagnosis?
□ Yes □ No
b. Do	  you	  think	  this	  term	  is	  appropriate?
□ Yes □ No
i. Why	  or	  why	  not?
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Diagnosis	  of	  Fabry	  Disease	  
8. Have	  you	  ever	  been	  diagnosed*	  with	  Fabry	  disease?
*A	  diagnosis	  can	  be	  made	  by	  genetic	  testing	  or	  by	  family	  history	  alone.
□ Yes □ No □ Unsure
If	  answered	  no	  or	  unsure,	  please	  continue	  to	  question	  8	  part	  f	  (page	  5).	  
If	  answered	  yes,	  please	  answer	  the	  following:	  
a. Which	  of	  these	  scenarios	  most	  accurately	  describes	  the	  situation	  that	  led	  to	  your
diagnosis?	  (Mark	  all	  that	  apply)
□ A	  family	  member	  was	  diagnosed	  with	  Fabry	  disease
□ My	  own	  symptoms
□ Other:	  _________________________________________________________________
b. Which	  center/clinic	  manages	  your	  diagnosis	  of	  Fabry	  disease?
□ Emory	  Genetics □ Weisskopf	  Child	  Evaluation	  Center
□ Massachusetts	  General	  Hospital □ Cincinnati	  Children’s	  Hospital
□ University	  of	  Washington □ Children’s	  Hospital	  of	  Wisconsin
□ Children’s	  Hospital	  of	  Chicago □ University	  of	  Colorado	  Hospital
□ Other:
c. Before	  you	  were	  diagnosed	  did	  you	  have	  any	  signs	  or	  symptoms	  of	  Fabry	  disease?
□ Yes □ No
i. If	  yes,	  mark	  all	  of	  the	  signs	  or	  symptoms	  that	  apply.
□ Proteinuria	  (excess	  protein	  in	  the	  urine) □ Kidney	  failure
□ Congestive	  heart	  failure	  (heart	  cannot	  pump
enough	  blood	  to	  meet	  the	  body’s	  needs)
□ Heart	  attack
□ Enlargement	  of	  heart □ Abnormal	  heart	  rhythm	  (irregular	  heart	  beat)
□ Stroke □ Transient	  ischemic	  attack	  (mini-­‐stroke)
□ Chronic	  pain □ Burning/numbness/tingling	  in	  hands	  or	  feet
□ Heat	  and/or	  cold	  intolerance □ Problems	  with	  sweating
□ Abdominal	  pain □ Diarrhea	  and/or	  constipation
□ Angiokeratomas	  (clustered	  red	  skin	  markings) □ Corneal	  whorls	  (pattern	  on	  transparent	  area	  of
eye	  only	  visible	  by	  slit	  lamp	  exam)
□ Pulmonary	  (lung)	  disease □ Depression	  and/or	  anxiety
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d. How	  did	  you	  feel	  about	  receiving	  a	  diagnosis	  of	  Fabry	  disease?	  	  Please	  describe.
e. Did	  your	  diagnosis	  of	  Fabry	  disease	  impact	  your	  ideas	  about	  your	  health?
□ Yes □ No
i. If	  yes,	  please	  describe	  how	  it	  impacted	  your	  ideas	  about	  your	  health.
If	  answered	  no	  or	  unsure	  to	  question	  8,	  please	  answer	  the	  following:	  
f. Have	  you	  been	  tested	  for	  Fabry	  disease?
□ Yes □ No
g. If	  you	  have	  not	  been	  tested,	  what	  are	  your	  reasons	  for	  not	  seeking	  testing?
Clinical	  Care	  and	  Monitoring	  of	  Fabry	  Disease	  
9. In	  the	  care	  of	  your	  Fabry	  disease,	  which	  of	  these	  evaluations,	  if	  any,	  have	  been	  recommended	  to
you?	  (Mark	  all	  that	  apply)
□ 24	  hour	  urine	  test	  (test	  for	  kidney	  function) □ Renal	  (kidney)	  biopsy
□ Electrocardiogram/EKG	  (records	  heart’s
electrical	  activity	  using	  electrodes)
□ Echocardiogram	  (ultrasound	  of	  the	  heart)
□ 24	  hour	  holter	  heart	  monitoring	  (cardiac	  event
monitoring)
□ Heart	  MRI	  (uses	  magnets	  to	  create	  a	  picture	  of
the	  heart)
□ Audiologic	  (hearing)	  evaluation □ Pulmonary	  (lung)	  function	  test	  (breathing	  test)
□ Brain	  MRI	  (uses	  magnets	  to	  create	  a	  picture	  of
the	  brain)
□ Slit	  Lamp	  eye	  exam
□ Fabrazyme	  antibody	  testing	  (blood	  test) □ GL-­‐3	  testing	  (blood	  or	  urine	  test)
□ Lipid	  panel	  (cholesterol	  blood	  test)
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a. Of	  the	  following	  evaluations	  recommended	  to	  you,	  which	  did	  you	  complete	  at	  the	  time
of	  your	  diagnosis?	  (Mark	  all	  that	  apply)
□ 24	  hour	  urine	  test	  (test	  for	  kidney	  function) □ Renal	  (kidney)	  biopsy
□ Electrocardiogram/EKG	  (records	  heart’s
electrical	  activity	  using	  electrodes)
□ Echocardiogram	  (ultrasound	  of	  the	  heart)
□ 24	  hour	  holter	  heart	  monitoring	  (cardiac	  event
monitoring)
□ Heart	  MRI	  (uses	  magnets	  to	  create	  a	  picture	  of
the	  heart)
□ Audiologic	  (hearing)	  evaluation □ Pulmonary	  (lung)	  function	  test	  (breathing	  test)
□ Brain	  MRI	  (uses	  magnets	  to	  create	  a	  picture	  of
the	  brain)
□ Slit	  Lamp	  eye	  exam
□ Fabrazyme	  antibody	  testing	  (blood	  test) □ GL-­‐3	  testing	  (blood	  or	  urine	  test)
□ Lipid	  panel	  (cholesterol	  blood	  test)
b. Of	  the	  following	  evaluations	  recommended	  to	  you,	  which	  do	  you	  continue	  to	  follow	  on	  a
regular	  basis?	  (Mark	  all	  that	  apply)
□ 24	  hour	  urine	  test	  (test	  for	  kidney	  function) □ Renal	  (kidney)	  biopsy
□ Electrocardiogram/EKG	  (records	  heart’s
electrical	  activity	  using	  electrodes)
□ Echocardiogram	  (ultrasound	  of	  the	  heart)
□ 24	  hour	  holter	  heart	  monitoring	  (cardiac	  event
monitoring)
□ Heart	  MRI	  (uses	  magnets	  to	  create	  a	  picture	  of
the	  heart)
□ Audiologic	  (hearing)	  evaluation □ Pulmonary	  (lung)	  function	  test	  (breathing	  test)
□ Brain	  MRI	  (uses	  magnets	  to	  create	  a	  picture	  of
the	  brain)
□ Slit	  Lamp	  eye	  exam
□ Fabrazyme	  antibody	  testing	  (blood	  test) □ GL-­‐3	  testing	  (blood	  or	  urine	  test)
□ Lipid	  panel	  (cholesterol	  blood	  test)
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10. Do	  any	  of	  the	  following	  prevent	  you	  from	  participating	  in	  recommended	  evaluations	  and
monitoring?	  (Mark	  all	  that	  apply)
□ Time □ Distance	  from	  centers
□ Difficulties	  obtaining	  transportation □ Costs	  not	  covered	  by	  insurance
□ Lack	  of	  insurance □ Insurance	  or	  work	  discrimination
□ Job	  Responsibilities □ Symptoms	  are	  not	  severe
□ Childcare	  responsibilities □ Care	  of	  family	  member	  affected	  with	  Fabry
□ Not	  enough	  information	  about	  assessments □ Frustration	  with	  the	  amount	  of
recommended	  tests
□ Poor	  Health □ Lack	  of	  support	  or	  encouragement
□ Frustration	  with	  lack	  of	  provider	  knowledge
about	  Fabry	  disease
□ Concern	  about	  test	  results/finding	  a	  health
problem
□ Fear	  of	  testing	  procedure(s) □ Worry
□ Sadness □ Feeling	  overwhelmed
□ Desire	  to	  keep	  focus	  on	  more	  severely	  affected
family	  member(s)
□ Guilt
□ Feeling	  undeserving	  of	  care	  or	  attention □ Anger	  about	  diagnosis
□ Depression/excessive	  sadness □ Anxiety/excessive	  worry
a. Please	  elaborate	  on	  any	  of	  the	  factors	  you	  marked	  above	  OR	  if	  there	  are	  any	  factors	  not
listed	  above	  that	  impact	  your	  participation	  in	  recommended	  evaluations	  and	  monitoring
please	  describe	  them	  here.
11. Are	  you	  currently	  receiving	  enzyme	  replacement	  therapy	  (ERT)?
□ Yes □ No
If	  answered	  yes,	  please	  answer	  the	  following:	  
a. What	  were	  your	  expectations	  for	  how	  ERT	  could	  improve	  your	  health?
b. Please	  describe	  how	  ERT	  did	  or	  did	  not	  meet	  your	  expectations?
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12. Please	  list	  any	  other	  issues	  or	  concerns	  regarding	  your	  Fabry	  disease	  not	  discussed	  in	  this
questionnaire.
We	  value	  your	  input.	  	  Thank	  you	  for	  completing	  this	  questionnaire.	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